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Chapter 1.  GENERAL INTRODUCTION 
SYSTEM’S BIOLOGY AND THE “OMICS” 
  The last two decades have witnessed a new era of research established after huge 
technological developments pertaining to the biological sciences.  These technological 
developments include mass spectrometry, arrays technologies and high-throughput sequencing 
analysis. These advances in technology opened the way for improved understanding of complex 
diseases and development of new therapies and diagnostics.  The outcome of the technological 
improvements was the capability to study large quantities of genes, RNA, proteins or 
metabolites simultaneously.  The advent of these methods added new terminology to the field 
of science, including genomics (first described in 1986), proteomics (1995), metabolomics 
(1998) (1, 2) as well as other “omics” like transcriptomics.  Genomics, transcriptomics, 
proteomics and metabolomics simply refer to the study of the complete set of cellular DNA, 
RNA, proteins and small molecules (metabolites) ,respectively.  Judicious use of several or all of 
these techniques simultaneously enables improved understanding of the complete operation of 
any living system, which could be an organism, tissue, cell or even part of a cell.  This broad-
scope study of living entities is simply termed “systems biology” (3) (Figure ‎1-1). 
 
 





  As shown in figure 1, metabolomics is the final step in the “omics” cascade, and the 
closest to the phenotype (4). Being the nearest to the phenotype, gives metabolomics the 
advantage of serving as a direct signature of biochemical activity and being described as “the 
apogee of omics” (5). Tools for comprehensive metabolomics analysis are still emerging and 
publications containing the word “metabolomics” have increased exponentially over the last 10 
years (Figure ‎1-2), but still in its infancy compared to other “omics” such as “proteomics”. The 
metabolome encompasses a large number of metabolites.  The number of known metabolites 
in human serum is estimated to be approximately 4000 (6), which jump to approximately 
40,000 metabolites when exogenous metabolites from food, drugs and the microbiome are 
included (7). The chemical diversity of the metabolome leads to the conclusion that, unlike 
genomics or proteomics, no single instrumental platform is able to analyze the entire 
metabolome (4).  
 
Figure ‎1-2: The frequency of metabolomics and proteomics term in literature. Bibliographic search using SciFinder using the 
term metabolomics or proteomics.    
 
METABOLOMICS PLATFORMS 
  The challenge in profiling cellular metabolome is not limited to the large number of 
metabolites but also involves the great heterogeneity in chemical properties and abundance of 
those metabolites.  The fact that these metabolites are only one part of a biological sample, 




complexity of the analysis. The most common platforms for metabolomic profiling and 
quantitation are nuclear magnetic resonance (NMR) and mass spectrometry (MS) instruments.  
NMR-based metabolomics platform 
  Application of NMR in metabolomics is very useful as it can provide a “holistic view” for 
metabolites in a complex sample.  It has many advantages, such as being non-destructive, so a 
sample can be re-used or re-measured several times.  It provides detailed structural 
information that can help identifying unknown metabolites. It does not depend on analyte 
polarity and requires minimal sample preparation such as separation or derivatization (8, 9). 
NMR is good for metabolite quantitation, providing reproducible correspondence between 
signal intensity and metabolite concentration. Different nuclei can be used in NMR; the proton 
is the most widely used nucleus due to its high abundance and resulting in higher sensitivity. 
Other nuclei like 31P and 13C can be used for phosphorus-containing compounds and flux 
analysis, respectively (10).  The main disadvantage of NMR in metabolomics is its relatively low 
sensitivity, rendering it non-suitable for low-abundance metabolites (9). Another drawback of 
NMR-based metabolomics is the challenge of identification of individual compounds in a 
complex mixture because of signal overlap (4). To reduce sample complexity, a prior sample 
separation can improve NMR identification but will further reduce the technique sensitivity as 
mentioned in the next sections.   
MS based metabolomics: 
  MS is typically more sensitive than NMR, with the lower limit of detection in the 
femtomole range for most metabolites compared to the low nanomole range for NMR (11). 
However, unlike NMR, MS is a destructive technique, where the sample is usually lost after 
analysis and can’t be reused. MS can measure several hundred of metabolites with various 
properties and concentrations simultaneously, as compared to NMR which typically detects 
high tens to just over 100 metabolites (9). MS can be used as a standalone platform by directly 
injecting the sample into the mass spectrometer or can be coupled to a separation technique. 
While direct sample analyses by mass spectrometer provides the shortest analysis time and a 
large range of metabolites can be covered (12), it has many disadvantages. Among these 




ionization suppression of less efficiently ionized molecules by other highly ionized ones.  
Another disadvantage is the lack of a separation dimension, which often provides an additional 
confirmation of a metabolites’ identity. Therefore, a typical MS-based metabolomics platform 
consists of a separation technique, a mass spectrometer and data analysis tools (Figure ‎1-3). 
Mass spectrometers vary in ionization and detection capability, which further affects 
metabolome analysis. These considerations are briefly discussed in the next section.  
 
Figure ‎1-3: Work flow for a typical MS platform for metabolomics. 
Ionization  
  In order for molecules to be analyzed by MS, they must be presented as ions in the gas 
phase. Several ionization techniques exist, however the most commonly used types in 
metabolomics are electropray ionization (ESI), atmospheric pressure chemical ionization (APCI), 
atmospheric pressure photoionization (APPI), electron impact ionization (EI) and matrix assisted 
laser desorption ionization (MALDI). These ionization techniques are complementary to each 
other, each having unique advantages and disadvantages which will be described briefly. 
Electron impact ionization (EI) is mainly suitable for volatile and thermally stable compounds, 
thus it is mostly used with gas chromatography (GC) separation methods. It has the advantage 
of providing a fingerprint-like fragmentation pattern for metabolites that can be searched 
against available spectral libraries (13). Recently the Fiehn lab has released a library of 
metabolites acquired by GC-EI-MS.  The initial number of metabolites in the library was ~ 2000, 
but it is continually increasing (14). One of the disadvantage of EI is that fragmentation of the 
metabolite is often so extensive that the parent ion is entirely absent from the spectrum, which 
will increase the challenge of determining the precursor mass (13). Extensive fragmentation 
also complicates the interpretation of mass spectrum (13). MALDI is a widely used ionization 




(15, 16) and provides quick analysis of metabolites in limited sample volume. However, MALDI 
has several disadvantages, mainly the difficulty of quantification and hyphenation to LC. The 
dried matrix-sample mixture is usually not homogenous, hindering quantification since the laser 
ionizes only a small portion of the sample in most cases. The hyphenation of a separation 
technique like LC is challenging, because it requires offline fractionation onto a MALDI plate.  
 Thus the three most common ionization techniques that are applied in metabolomics 
and can be hyphenated to liquid chromatography are ESI, APCI and APPI. These three modes of 
ionization have been compared before by several groups and their results confirm the 
complementarity of the three methods, although ESI offers the greatest extent of global 
metabolome coverage (17, 18).  Because APPI or APCI involve application of high levels of heat, 
several metabolites including glycerophospholipids have been shown to fragment with those 
sources, unlike ESI (17). Neutral lipids have shown better linear response with APPI and APCI 
than ESI, however ESI offered improved limit of detection (via adduct formation) (19).             
Mass analyzers 
  Choosing an appropriate mass analyzer is crucial in metabolomics studies, since 
different outputs are obtained from different types of instrumentation. If the goal is to analyze 
the concentration of a specific set of metabolites in a complex matrix, then a triple quadrupole 
mass analyzer is an ideal option. A quadrupole (Q) has limited resolution and mass accuracy 
which limits its application to identify metabolites. However, the low mass accuracy is 
compensated by the specificity of “multiple reaction monitoring” (MRM), a technique which 
can be performed using triple quadrupole MS instruments (QQQ).  In MRM, a precursor ion is 
selected in Q1 and fragmented in Q2 by collision with gas molecules (collision induced 
dissociation) and fragments are then selected for quantification in Q3.  This process excludes 
most ions except those that originate from the specific metabolite of interest, thus resulting in 
a high signal-to-noise ratio. However, the slow scanning speed of quadrupole limits the number 
of metabolites that can be analyzed simultaneously.  If the primary goal is to identify and 
analyze as many metabolites as possible, then high scan speed and high resolution mass 




cyclotron resonance instrument (FTICR), followed by the Orbitrap, followed by the time of flight 
mass analyzer (TOF) (Figure ‎1-4). Although the higher resolution of FTICR and Orbitrap 
instruments enables resolution of metabolites with similar masses and allows more definitive 
identification of unknown metabolites, they are not widely used in metabolomics (Figure ‎1-4).  
The less frequent application of these instruments in metabolomics is due to their substantially 
higher cost and the fact that their maximum scanning speed is several fold-lower than a TOF 
(20).   
    
Figure ‎1-4: The frequency of the application of different mass spectrometers in metabolomics. Bibliographic search using 
Scifinder. The word metabolomics was searched followed by refining the results by the key words:  “time of flight”, 
“quadrupole”, “Orbitrap” and “FTICR”. 
COMMON SEPARATION TECHNIQUES IN METABOLOMICS 
  As described above, separation is very important in metabolomics studies. Metabolite 
separation decreases sample complexity and provides further information about metabolites’ 
chemical characteristics that aid in their identification (21).  Separation can be utilized in both 
NMR and MS metabolomics platforms. Separation is crucial in mass spectrometry based 
metabolomics, since it allows the detection of low-abundant metabolites whose ionization 
could be suppressed by higher-abundant ones.  Direct coupling of separation techniques such 
as liquid chromatography to NMR is complicated and suffers limitations that reduce the 




during transport to the NMR flow cell; dilution of the chromatographic peak which occurs 
during filling of the flow cell, and challenges in chromatographic peak selection (22).  Common 
separation techniques used in metabolomics include gas chromatography, liquid 
chromatography and capillary electrophoresis. These separation techniques are 
complementary to each other, each having pros and cons that are described briefly below. 
Gas chromatography:  
  Gas chromatography has been regarded as the gold standard for metabolite analysis for 
several years (21).  It is usually connected to a mass spectrometer equipped with an EI 
ionization source, which renders it less prone to ionization suppression from co-eluting 
compounds, unlike LC-MS (23).  GC-MS requires that the metabolite be thermally stable and 
volatile, which are not common features for many polar metabolites. Thus, chemical 
derivatization to increase volatility is a requirement for many metabolites in order to widen the 
application range of this technique (24).  Common drawbacks of derivatization include the loss 
of sample during derivatization, and the difficulty of identifying compounds because of the 
unknown or incomplete reaction of derivatization reagent molecules with unknown 
metabolites (25). Thus, identifying metabolites through an undirected analysis approach is 
often dependent on the availability of spectra of authentic standards in GC-MS libraries. 
However, GC-MS offers an excellent complementary technique to LC-MS, enabling detection of 
many metabolites that are not amenable to LC-MS analysis. 
Liquid chromatography.  
  Liquid chromatography coupled to mass spectrometry (LC-MS) represents the technique 
of choice for global metabolite profiling (5). LC/MS allows the detection of thousands of peaks 
from biological samples. Peaks with unique mass and retention time are called “features”. The 
particle size of stationary phases ranges from 5 µm to 3 µm for conventional high pressure 
liquid chromatography “HPLC” or sub-2 µm for ultra pressure liquid chromatography “UPLC”. 
The advantage of UPLC is the reduction in total run time, improved separation efficiency by 
reduction in eddy diffusion and mass transfer kinetics. Elution of metabolites as sharper peaks 




features (21, 25). As described above, metabolites vary in polarity, charge and stability. Thus, 
no single separation technique is able to resolve a complex sample, and orthogonal separation 
mechanisms should be used to ensure wider metabolome coverage (21).  The combination of 
both reversed phase liquid chromatography (RPLC) and hydrophilic ion interaction 
chromatography (HILIC) methods provides a wide range of metabolome coverage (26). C18 is 
the most widely used RPLC stationary phase for the separation of non-polar metabolites. It 
provides a reproducible and predictable retention time, and effectively resolves a wide range of 
hydrophobic metabolites and lipids (21). However, hydrophilic metabolites are mainly eluted 
non-retained in the void volume.  
  HILIC separation is an orthogonal technique to RPLC. Several stationary phases have 
been developed for HILIC, each with different functional groups that provide different 
selectivity and separation mechanisms (27). Functional groups in HILIC stationary phase include 
the amino-propyl, amide and diol groups. The major drawback of HILIC is the increase in 
retention time drift relative to RPLC (21) as well as shorter column life.  A new modification for 
HILIC was recently introduced, which is aqueous normal phase (ANP), based on a silica hydride 
stationary phase, that was shown to have more stable retention time (28). However for the 
coverage of metabolites associated with central carbon metabolism, our lab and others (26) 
have determined that the amino-propyl (29) HILIC column still offers the best coverage.  
Capillary electrophoresis  
  Capillary electrophoresis (CE) separates metabolites based on their electrophoretic 
mobility, which is dependent on metabolite hydrodynamic radius (size)-to-charge ratio (30). 
Like LC, CE can be directly coupled to mass spectrometry by electrospray ionization.  CE-MS has 
shown success in several metabolomics studies (31-37). Although it provides faster analysis and 
potentially higher resolution separations than LC, it is not as widely used in metabolomics (30) 
compared to chromatographic techniques described above (Figure ‎1-5). Among the limitations 
of CE are the low maximum injection volume (a few microliters for CE compared to hundreds 
microliters for LC or GC) (21). Also, since the capillary length and background electrolyte (BGE) 




migration time of metabolites; however, relative migration time compared to a standard can be 
utilized (21, 30). Difficulties that are associated with the coupling of CE to MS are what really 
limit the widespread application of this technique in different labs (30). ESI-MS hyphenation to 
CE is not as straightforward as with LC, because a closed electrical circuit is required for both 
the CE separation and for ionization on the ESI-MS (38). Buffers normally used as a BGE for CE 
are not MS compatible, so these buffers need to be substituted with volatile MS-compatible 
buffers, which provide reduced quality of separation (39). Common CE-MS interfaces include 
both sheath and sheathless flow. Sheath flow involves using a co-axial liquid effluent to achieve 
electrical contact with the CE effluent; however, it causes post-capillary dilution (21, 39).  
Sheathless flow is still under development and few configurations have shown sufficient 
robustness for routine metabolomics analysis (21).      
 
 
Figure ‎1-5:The frequency of the application of chromarography or electrophoresis in metabolomics. Bibliographic search 
using SciFinder using the word metabolomics and metabonomics, and further refined using either the term chromatography 
or electrophoresis. 
As evidenced by the preceding discussion, multiple analytical strategies can be used to 
perform metabolomics research.  While no method is comprehensive, careful selection of an 
appropriate analytical strategy is important to ensure all aims of a study can be met.  In light of 
these considerations, the work described in this dissertation was performed by liquid 






























metabolites. Both chromatographic methods were directly coupled via ESI ionization to a TOF 
high resolution mass analyzer.   
DIRECTED AND UNDIRECTED METABOLOMICS 
  After the selection of an appropriate separation and detection method, experiment 
design is the next critical stage of metabolomics research. Two major approaches are available, 
which are targeted (directed) and untargeted (undirected) metabolomics. Directed analysis is 
the approach in which a specific set of metabolites are measured, usually focusing on one or 
more related pathway(s) of interest (40). In directed analysis, the analytical method (separation 
and detection) is optimized for the desired set of metabolites using authentic standards.  This is 
followed by applying the method to biological samples, and reporting the results for this set of 
metabolites (Figure ‎1-6).  On the other hand, undirected metabolomics is the approach which 
aims to analyze as many metabolites as possible (40). In undirected analysis (Figure ‎1-6), a 
global separation and detection method should be applied that can separate and detect a wide 
range of metabolites. It also requires a high resolution mass spectrometer (as described in the 
mass analyzers section) to accurately determine the mass and help to identify those 
metabolites. This global measurement is followed by extensive data analysis procedures 
described in the next section.    
 





  Data analysis techniques differ substantially between targeted and untargeted 
approaches. Data analysis for targeted metabolomics is relatively simple, where metabolites of 
interest are identified based on their mass and retention time matching with that of an 
authentic standard. Quantification can be performed by measuring metabolite peak area or 
peak height using the MS vendor software. Untargeted metabolomics involves several extra 
steps compared to targeted analysis.  The first step is to identify features (peaks) with a specific 
mass and retention time.  A normal LC-MS run contains, on average, a few thousand features, 
which necessitates automation of this step. Algorithms for feature selection software should be 
able to differentiate between a chromatographic peak and noise.  Although seemingly simple, 
this task is usually performed imperfectly by all current software and thus requires manual 
inspection of the data. The second step is to align all features that are in common between 
different samples to allow for quantitative comparison in subsequent steps. The alignment step 
is a crucial issue, especially in HILIC-LC-MS, because of retention time shifts that occur through 
different samples. Shifts in retention time may arise from degradation of the column, change in 
mobile phase pH and sample carry over.  The third step is to quantitate the data and measure 
the metabolites’ relative abundances in different sample groups.  Then, various methods of 
statistical analysis can be used to determine which metabolites differ significantly between 
sample groups.  
  The difference in features across groups can be visualized using different plots, including 
scatter plots, heat maps, volcano plots and cloud plots (Figure ‎1-7), with the later being the most 
comprehensive (41). Several software programs have been developed by many groups to 
facilitate and automate these steps, such as XCMS (42), MathDAMP, Metalign, and MZmine (5). 
Major mass spectrometer vendors have also developed software compatible with data from 
their systems to help in determination of differential abundance of metabolites and other 
biomarkers; some of these software packages include Mass Profiler by Agilent, SIEVE from 
Thermo Scientific, Marker View from Ab Sciex and MarkerLynx from Waters.  The next step is to 
search the accurate mass of features of interest against different metabolite databases. 




base (HMDB), Kyoto encyclopedia of genes and genomes (KEGG), Mass bank, Madison 
metabolomics consortium database (MMCD) and lipid maps which is specialized in lipids (42). 
The final step is to confirm the identity of these database hits, when possible, by matching the 
retention time of the metabolite with that of a standard, and by using MS/MS.  When a 
metabolite standard is not available, an alternative approach is to expose living cells to a 
labeled precursor of this metabolite, such that the cells will generate a new labeled standard 
that can confirm the identity of this metabolite (this process is described in detail later in the 
dissertation). The unique identification of metabolites remains a challenging step in some 
cases, although identification of lipids has recently been improved due to the availability of in-
silco MS/MS fragmentation data contained within the “Lipid Blast” database (43). 
 
Figure ‎1-7: data visualization tools in metabolomics. 
FLUX ANALYSIS 
  The previously-described directed and undirected metabolomics approaches enable 
quantitation of any increase or decrease in the abundance of specific metabolites within a 
biological system.  These data clearly may provide useful information regarding the possible up-
regulation or down-regulation of particular metabolic pathways. However, not every possible 
alteration in a metabolic pathway will necessarily be reflected as absolute changes in 
metabolite levels.  It is possible for certain metabolic pathways to be differentially regulated 
between sample groups, but yet the absolute levels of metabolites remain constant because of 
different compensatory mechanisms.  To reveal the true alteration in the metabolic pathways 
in such a scenario would require another level of metabolomics investigation.  One excellent 




The resulting technique, termed metabolic flux analysis, or MFA, is a key method to analyze and 
quantify in vivo rates of metabolic reactions (44).  Different stable-isotope-labeled metabolic 
tracers can be used that include 13C , 2H, 15N, and 18O (45). In many cases 2H readily exchanges 
with protons from water and other molecules; hence incorporation into the metabolome is not 
stable compared to 13C. Both 13C and 2H can be used to assess flux in nearly all metabolites, 
while 15N is mainly used for flux monitoring in nucleic acid and proteins, and 18O is less 
commonly used.   Because of the complexity of metabolic networks, mathematical modeling is 
needed to analyze flux in multiple metabolic pathways; the use of such techniques has been 
described in detail elsewhere (44). Mass isotopomer analysis is different from MFA, since the 
former does not measure metabolic flux or rate; it measures the distribution of carbons in 
specific metabolites. Using a metabolic tracer, mass isotopomer analysis enables the 
measurement of metabolites’ isotopic enrichment. The isotope enrichment data provide useful 
information about pathways being utilized by metabolic tracers. Application of metabolic tracer 
to investigate metabolic pathways is described in chapter 2, 3, 4 and 5.  
METABOLOMICS APPLICATIONS 
  By applying the analytical and data analysis tools just described, metabolomics has been 
successfully implemented in a wide range of challenges in various fields of biological research. 
Metabolomics has been applied to study metabolism in plants, animals and microorganisms. In 
plant science, metabolomics has been used to understand gene function and molecular 
breeding and to discover new phytochemicals that can be used for different purposes like 
pharmaceuticals (46). Metabolomics of biofluids and tissues from living animals has 
demonstrated successful identification of pathways involved in animal development and also in 
research involving disease and drug discovery (46). Microbial metabolomics is also currently of 
great interest, both because of potential industrial applications such as biofuel generation (47, 
48), and due to the increasing interest in gut flora (termed the “microbiome”) (49).  A human 
being harbors ~ 100 trillion bacterial cells in his or her gut, a quantity 10 times greater than that 
of human cells in the same organism.  This enormous amount of bacteria metabolizes food 
products and generates metabolites that participate in the development of several diseases and 




phosphatidylcholine (50, 51) and carnitine (52) metabolism by gut flora. Similar association of 
gut flora to diabetes and obesity has also been demonstrated (53-59), suggesting that flora 
modulation may provide an alternative approach for treatment of these complex diseases.  
Metabolomics has also been applied to the study of a variety of other diseases including cancer, 
psychological disorders, obesity and type 2 diabetes mellitus (T2DM) (46).  The latter two 
conditions will be the primary focus of the metabolomics-based research presented in 
remainder of this dissertation.  
APPLICATION OF METABOLOMICS TO THE STUDY OF TYPE 2 DIABETES  
Background on diabetes: 
  Diabetes is a chronic disease that is characterized by high blood glucose levels 
(hyperglycemia), which is caused by relative deficiency of insulin hormone. Diabetes is classified 
as type 1 or type 2 based on the etiology of the insulin deficiency.  In type 1 or juvenile 
diabetes, an autoimmune response destroys β-cells located in the pancreas, usually in 
childhood, which causes a complete loss of insulin secretion (Figure ‎1-8). In type 2, insulin 
resistance develops in the skeletal muscle and other organs, which leads to compensatory 
increase of insulin secretion into the blood by β- cells, resulting in hyperinsulinemia (Figure ‎1-8).    
Continuous increase of insulin secretion ultimately leads to the loss of β- cell function and the 
development of type 2 diabetes (60). The prevalence of diabetes in 2008 was estimated to be 
347 million people worldwide (61, 62), which is ~ 5% of the estimated population of the earth. 
In the US alone, 25.8 million people were diagnosed with diabetes in 2011, representing 8.3 % 
of the US population (63). About 90 % of diabetic patients are diagnosed with type 2 diabetes 
(64). 
   The main complications of hyperglycermia are associated with its long term effects on 
other organs, which include micro and macro vascular complications that can be fatal (Figure 
‎1-8). It is important to highlight that type 2 diabetes is a metabolic disorder, in which high 
glucose and high fatty acids, acting in concert with certain genetic factors, lead to β- cell toxicity 
and the development of the full range of medical complications associated with type 2 diabetes 




disease, metabolomics provides a particularly useful strategy to gain insight into the molecular 
factors that contribute to this disease. 
            
 
Figure ‎1-8: diagram for diabetes etiology and consequences, adapted from (60) 
Metabolomics as a method to study type 2 diabetes 
  During the last decade, the growing field of metabolomics has offered new insights into 
the pathology of diabetes as well as biomarkers that can predict disease onset (64).  Several 
biomarkers that are related to carbohydrate, lipid, amino acid, choline and bile acid metabolism 
have been shown to be up- or down-regulated in T2DM patients and have been thoroughly  
reviewed elsewhere (64, 65). Among the most common biomarkers are changes in amino acid 




phenylalanine and tyrosine showed elevation in individuals susceptible to T2DM (66), and were 
detectable as elevated as early as 12 years before the onset of disease (67) . Lower levels of 
glycine (68), glutamate, and theronine were seen in T2D (66, 69). These data suggest the 
potential impact of amino acids on insulin action and glucose metabolism (64). Metabolites in 
lipid metabolism pathways also represent major biomarkers in diabetic patients.  Acyl-
carnitines have been shown to accumulate in the plasma of obese and diabetic patients, 
indicating a defect in fatty acid oxidation (70), together with accumulation of fatty acids and 
some forms of phosphatidylcholines (68).     
Animal models and β- cell lines 
  Several animal models have been developed to study T2DM development and 
treatment. Understanding and treating the disease in human subjects is the ultimate goal, but 
the development of the disease and its complication in humans takes years. This long time and 
high cost for assessing intervention outcome in the disease progression, makes animal models 
of T2DM a very attractive option. Animal models develop the disease and its complications in 
shorter time spans and are more cost efficient (71). Rodent animal models, especially mice and 
rats, have been widely used because of the complete sequencing of their genome, the ease of 
genetic manipulation, their relatively short breeding spans, and the ability to perform 
physiological and invasive testing (71). Mouse models include the obese (ob/ob) mice and the 
diabetic (db/db) mice, which have a knockout of the gene responsible for production of leptin 
or leptin receptor, respectively (71, 72). The most known rat model of T2DM is the ZDF rat, 
which has a similar mutation to leptin receptor as the (db/db) mouse. 
  In addition to studies involving live animals, additional insight can be gained through 
studies of specific, isolated tissues involved in the development of T2DM.  Of particular interest 
is the interaction of glucose and other nutrients on insulin secretion in pancreatic β- cells.   
Therefore, studies using islets obtained from human volunteers or animal models are of 
substantial interest.   However, isolated islets have several issues. The first is that non-β-cells 
contribute to ~ 40% of the mass of islets, and these cells which have different signaling 




of islets may result in retention of some pancreatic exocrine tissue, which will be a variable in 
quantity from one sample group to another.  Also, there is a risk of necrosis of inner cells in 
islets after isolation and culture because of the limited supply of O2 and nutrients to those cells 
(73). Beside those issues, since islets are very small microorgans and only limited quantities can 
be practically obtained for experimentation, performing metabolomics on islets is limited by 
low levels of metabolites and the need for relatively large number of islets per sample group to 
overcome the variation of sizes between islets. 
  These challenges led to the development of immortalized β- cell lines derived from 
rodent pancreatic tumors.  Studies of these cell lines has been shown to be very effective in 
understanding fuel signaling in β-cells (73). The cell lines have the advantage of producing 
homogenous, pure β-cells.  Limitations in quantities of cells are no longer a concern, as cells can 
be cultured in vitro until the needed amounts are obtained. For metabolomics, β-cell lines have 
the advantage that they can be cultured in a consistent manner, providing replicates with 
nearly equal cell numbers. The most widely used rat-derived β-cell lines are INS-1 cells, while 
the widely used mouse-derived β-cell lines are MIN-6 cells. Human β-cell lines have been 
recently described (74-76) but their availability are limited and their usefulness for 
metabolomics studies are yet to be investigated (73).  
  In spite of the utility of β-cell lines to gain understanding of the mechanism of insulin 
secretion, β-cell toxicity is still thought to be better studied using islets.  Due to their derivation 
from cancerous tumors, β-cell lines may have a compensatory mechanism that can relieve 
lipotoxicity that might not be available in normal islets. Nevertheless, metabolomics has 
provided valuable information for understanding the mechanism of insulin secretion, which is 
described in the following sections.     
Glucose stimulated insulin secretion  
  Glucose stimulates β- cells to secrete insulin in a biphasic manner. The first phase is 
called the KATP dependent pathway and it starts a few minutes after glucose stimulation and 
subsequently declines. It is considered ATP-dependent because the metabolism of increased 




closure of KATP channels and cell depolarization. Voltage dependent calcium channels open 
subsequently and increase calcium influx into the cells, which causes insulin exocytosis (77, 78). 
Second-phase insulin secretion acts in synergy with the first phase, starting a few minutes after 
the first phase, and reaches its maximum at ~ 30-40 minutes after glucose stimulation (78).  It is 
called the KATP-independent pathway, since glucose metabolism generates several other 
coupling signals that facilitate insulin exocytosis (77). Although not well understood, some 
coupling factors for this pathway are GTP, NADPH, LC-CoA, glycerolipids, glutamate, PEP, 
malonyl-CoA and others (73, 77, 78) (Figure ‎1-9). 
                            
Figure ‎1-9: glucose stimulated insulin secretion proposed pathway, adapted from (73) 
  Although glucose is the most potent insulin secretagogue, some amino acids and other 
nutrients are also known to stimulate insulin secretion alone or in combination with each other, 
including leucine, glutamine, BCH, ketoisocaproate (KIC), methyl ester of succinate (MMS), 
acetoacetate, β-hydroxybutarate and  fatty acids (79, 80). The main theory behind the activity 
of these different secretagogues is their ability to increase TCA cycle activity, which will increase 
ATP as well as different metabolic intermediates. The increase in both acetyl-CoA and 
oxaloacetate is required to ensure that the TCA cycle will be activated, and generates citric acid 
(Figure ‎1-10). Thus the function of those secretagogues (81) can be represented by the 





Figure ‎1-10: simplified pathway for secretagogues mechanism of insulin secretion. 
  Leucine activates glutamate dehydrogenase, increasing α-ketoglutarate and 
consequently oxaloacetate. At the same time it is metabolized into acetyl-CoA, therefore it can 
stimulate insulin secretion on its own. KIC is metabolized into leucine through a reaction that 
converts glutamine into glutamate, increasing α-ketoglutarate. It then acts as leucine, activating 
glutamate dehydrogenase and increasing acetyl-CoA.  Therefore it can stimulate insulin 
secretion independently, and has been shown to be even more potent than leucine (81). 
   BCH is a non-metabolizable leucine analog, which only activates glutamate 
dehydrogenase, increasing α-ketoglutarate. Therefore, BHC is a weaker secretagogue than 
leucine (81). Glutamine can increase the level of α-ketoglutarate and hence oxaloacetate, but it 
cannot stimulate insulin secretion on its own. Addition of leucine to glutamine will provide the 
acetyl-CoA necessary for TCA cycle activation and the stimulation of insulin secretion (81). Β-
hydroxybutare is metabolized into acetyl-CoA, but cannot stimulate insulin secretion on its 
own. Addition of methyl ester succinate (MMS) will ensure the availability of oxaloacetate 
necessary for TCA cycle activation and the stimulation of insulin secretion (79).Fatty acids 
cannot stimulate insulin secretion on their own, but can augment GSIS by the activation of the 





  The goal of the research presented in this dissertation is to enhance understanding of 
the interaction of glucose and fatty acids to modulate insulin secretion. Understanding of 
glucose and fatty acid interaction requires an analytical method(s) that can probe glucose and 
fatty acid metabolism inside β- cell. Application of stable isotope labeling is important to 
monitor the extent of this interaction. Thus, chapter 2 describes method development for lipid 
analysis, while the appendix shows the application of different metabolic tracers to probe 
metabolic pathways involved in insulin secretion. We applied those methods in chapter 3 to 
understand how glucose stimulates insulin secretion and to probe important pathways that are 
involved in GSIS. Chapter 4 describes the mechanism of fatty acid can potentiate GSIS and 
explains how fatty acid is metabolized in β- cell and how this metabolism can affect glucose 
metabolism. Chapter 4 also describes the role of free fatty acid receptor (FFAR/GPR40) in 
controlling glucose and fatty acid metabolism. Chapter 5 describes the effect of starvation on β- 
cells using a starvation/exercise mimetic drug. Finally, Chapter 6 describes some future 
research plans, which involve studying the chronic toxicity of glucose and fatty acids,  
understanding how other secretagogues can stimulate insulin secretion and the application of 
metabolomics to human β- cell lines that were recently established.      
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Chapter 2.  METHOD DEVELOPMENT FOR LIPID ANALYSIS. 
INTRODUCTION 
The importance of lipids in insulin secretion. Lipids are a class of biomolecules that are diverse 
in structure and function. Eukaryotic cells can have over a dozen classes of lipids, where each class can 
have hundreds of individual molecular species (1).  Lipids have multiple functions; they not only form 
the lipid bilayer and cellular matrix but also act as storage for energy sources and provide signaling 
molecules (1).  
Lipid signals are of great important in insulin secretion and β- cell function. Glucose stimulated insulin 
secretion is known to be mediated through glucose metabolism which stimulates the generation of lipid 
signals that facilitate insulin exocytosis (2). Short term exposure of β- cells to fatty acid will generate 
lipid signals that contribute to the amplification of glucose stimulated insulin secretion (3, 4). On the 
other hand, long term exposure to fatty acid can contribute to β- cell dysfunction and impairment of 
insulin secretion (5-7). 
Glycerolipids and glycerophospholipids are the most abundant lipid classes in cells.  They can be 
thought of as the linkage between glucose and fatty acid. Their synthesis starts by the condensation 
between glycerol-3-phosphate and acyl-CoA to form lysophophatidic acid (LPA), which then forms other 
glycerolipids/glycerophospholipids (figure 1). Some glycerolipids have been suggested to act as a signal 
for insulin secretion (5). Ceramides, on the other hand, are part of the sphingolipid class, and are known 
to induce β- cell apoptosis (8). Fatty acid amides are a novel class of lipids that were recently discovered 
in neuronal cells and involve the linkage between a fatty acid and an amino acid like glycine and taurine 
(9). N-palmitoyl glycine and acyl-taurines were recently shown to increase calcium flux in neuronal cells 
(10) and β- cells (11) respectively.  Acyl-carnitines are intermediates in the fatty acid oxidation pathway 
and are known to be a marker for insulin resistance and type 2 diabetes (12). The balance between fatty 
acid oxidation and esterification into lipids is crucial for insulin secretion (13) . The structure and the 






Figure ‎2-1: Chemical structure of different lipids classes 
 
Figure ‎2-2: Metabolic pathways for different lipids classes. Red lipids can be detected in negative mode ionization mode; 
blue lipids can be detected in the positive mode ionization mode. 
 
Separation and detection of non polar metabolites. The analysis and detection of lipids has 
improved dramatically in recent decades.  In the 1980s, lipid classes were mainly separated by thin layer 
chromatography (TLC) followed by the determination of the whole total fatty acid composition using gas 
chromatography coupled to MS. This method was widely applied but it suffered from low throughput 
and the need of high sample quantity. It also does not differentiate phospholipid species within each 




resolution mass spectrometry (1). The application of mass spectrometry increased throughput of lipid 
analysis and provided a wealth of detailed information about different lipid species. Global profiling of 
lipids can be performed in both negative and positive mode ESI-MS, with different classes of lipids 
appearing in each ion mode depending on their ionizable head group (figure 2).  
Although lipid extracts can be injected directly into the MS using the shotgun lipids approach 
(15), this technique suffers from high ion suppression of less abundant lipids and the difficulty of lipid 
identification. Performing flux experiments using labeled isotope nutrients further increases the sample 
complexity because it increases the number of lipids isotopes and requires a significant separation of 
lipid species to avoid overlap of masses.  The two main methods for lipid separation are normal phase LC 
and reversed phase LC. Normal phase LC separates lipids classes based on their head group, while 
reversed phase LC separates based on the chain length of the fatty acid. Hydrophilic interaction liquid 
chromatography (HILIC) provides similar separation characteristics to normal phase chromatography, 
but with more convenient coupling to a mass spectrometer, especially when ESI is used (16) (figure 3). 
Different lipid classes were successfully separated using HILIC (17-19); however, it yields poor peak 
shape for many lipid classes and certain classes co-elute, which complicates identification. Reversed 
phase separation was successfully implemented for global lipid profiling (20, 21); however, long 
gradients (more than 60 minutes) were required to obtain good separation and peak shape. Two 
dimensional LC approach was used to separate lipids classes first using a normal phase column (22) or by 
solid phase extraction (21), followed by fractionation and injection into a RPC column. Although this 
approach allowed the identification of low abundant species, like phosphatidyl serine, it suffers from 
low throughput and complexity of data analysis. 
Simultaneous extraction of polar and non polar metabolites. Polar and non polar metabolites 
are known to modulate insulin secretion (see chapter 1 for details), thus analyzing those diverse classes 
are equally important in understanding insulin secretion. Undirected metabolomics also requires an 
analysis of as many metabolites as possible, so it requires unbiased metabolite extraction and detection 
methods.  
The traditional methods for lipid extraction from biological tissues use a two-layer solvent method that 
separates the lipid rich organic phase from the protein and salt rich aqueous phase. Methanol, 
chloroform and methyl tert- butyl ether (MTBE) are the most common organic solvents used in these 
two phase extraction methods (23).   These extraction methods are not designed for the extraction of 




reconstitution. Recent work tried to recover polar metabolites from the aqueous layer to allow for the 
simultaneous extraction of both polar metabolites and lipids (24). This method suffered from low 
throughput because of multistep extraction, phase separation and drying. Evaporation of the aqueous 
layer was not practical because of the high level of water and proteins in this layer. Relatively high 
temperature and long time used in the aqueous layer evaporation as well as the increased levels of 
proteins and enzyme activity, might lead to degradation of some metabolites. Probably these 
complications led to the reporting of acyl carnitines and fatty acids as a representative of the polar 
fraction, while nucleotides and metabolites in the central carbon metabolism pathway were ignored.  A 
single-layer extraction using 100% methanol was reported to achieve similar lipid recovery to the two 
layer traditional methods (25), however the ability of this method to recover or analyze polar 
metabolites extraction was not addressed.  Recent work described undirected metabolomics platform 
using single extraction solvent for polar and non polar metabolites (26). However, the lipids reported 
using the reversed phase analysis were mainly polar-lipids, such as acyl-amides and carnitines, and no 
attempt was made to analyze other moderately or highly non polar lipids such as most glycerolipids.  
 
   
                           
 
Figure ‎2-3: lipid separation mechanism using HILIC or RPC chromatography 
 
To the best of our knowledge there is no comprehensive study that described simultaneous 
extraction of polar metabolites such as glycolysis and TCA cycle together with non polar metabolites 




chromatographic conditions such as column stationary phase, temperature and pH on lipid separation 
and detection. Most methods reported using C18 column, with acidic or uncontrolled mobile phase pH 
and a set temperature, without reporting the reason of those adjusted parameters. 
 Thus we decided to develop and optimize an LC-MS based platform that can be used for 
extracting and analyzing lipids and polar metabolites from adherent cell lines. Lipids of interest were 
those classes that are known to be involved in insulin secretion such as glycerolipids, acyl- carnitines, 
ceramides and acyl amides. We evaluated different methods for lipid separation, mainly using a HILIC 
column (amino propyl) that is used for polar metabolites analysis as well as several reversed phase 
columns (RPC) with different stationary phases (C18, C8 and C30).  HILIC separation showed a superior 
performance compared to RPC in phosphatidyl serine class separation, while C18-RPC columns showed 
improved separation for most other lipids classes. C18 showed better separation efficiency than C8 for 
phosphatidic acid and tripalmitin. C30 showed higher resolution than C18 in separating positional 
isomer lipids, which could be useful if such resolution is important to biological interpretation, but it 
otherwise complicates metabolite profiling. Then we decided to further optimize a C18 separation 
method by evaluating different operating conditions including temperature and mobile phase pH and 
their effect on lipids separation and stability. Optimizing the separation method was followed by 
screening different extraction solvents for lipid extraction efficiency including MTBE or combinations of 
methanol and chloroform. Single layer extraction solvent was as efficient as the traditionally used 2 





MATERIALS AND METHODS: 
Materials.  INS-1 cells (832/3) were kindly provided by Dr. Christopher Newgard (Sarah W. Stedman 
Nutrition and Metabolism Center, Duke University, Durham, NC).  All chemicals were purchased form 
Sigma-Aldrich (St. Louis, MO) unless otherwise noted. RPMI media, fetal bovine serum, 4-(2-
hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), and penicillin-streptomycin were purchased 
from Invitrogen Corp, (Carlsbad, CA).  
Cell culture.INS-1 832/13 cells were cultured in RPMI supplemented with 2 mM glutamine, 1 mM 
sodium pyruvate, 10% FBS, 10 mM HEPES, 100 U/mL penicillin, 100 µg/mL streptomycin, 250 ng/mL 
amphotericin B, and 50 µM β-mercaptoethanol.  Cells were plated at a density of ~14 x 103 cells/cm2 
and grown in 6 cm culture dishes at 37 °C and 5% CO2 in a humidified atmosphere to ~70% confluence. 
Krebs-Ringer-HEPES buffer (KRHB) was prepared containing  20 mM HEPES, 118 mM NaCl, 5.4 mM KCl, 
2.4 mM CaCl2, 1.2 mM MgSO4, and 1.2 mM KH2PO4 and was adjusted to pH 7.4 with NaOH.  Cells were 
incubated with 500 uM palmitic acid in KRHB for 45 minutes before being quenched. Each cell plate was 
extracted with 400 ul x two times of 8:1:1 methanol: chloroform: water. All extracts were pooled 
together to form a pooled sample for evaluation of different columns, temperatures and pH values. For 
comparing different extraction solvents, equal volumes of methanol were added to the cell plates and 
cells were transferred to a glass tube. Two parts of chloroform were added to the methanol extract for 
the Folch method, or two parts of MTBE were added for the MTBE method.  
LC-MS. Reversed phase columns (RPC) were tested in pairs depending on their particle size:  Capcell, 
C18 column vs. Thermo, C-30 column (both are 3 µm x 150 mm x 2 mm) and Waters C18 column vs 
Waters C-8 column (both are 2.5 µm x 150 mm x 2 mm). Luna NH2 (3 µm x 150 mm x 2 mm) was tested 
for the HILIC mode of separation. Solvents for reversed phase separation were as follows: A is (40% 
water, 40% Acetonitrile and 20 % methanol) and B is (80% isopropanol and 20% methanol). Both 
solvents are supplemented with 0.1 % formic acid and 0.028% ammonium hydroxide (MS grade) unless 
otherwise mentioned in the pH adjustment. The gradient for RPC started at 0% B and increased to 60% B 
in 10 minutes, then increased to 80% in 40 minutes, then increased to 100%B in 5 minutes, than held at 
100% B for 10 minutes before going back to 0 % B in 0.1 minute and holding for 15 minutes. 
Temperature was kept at 35°C for the whole run unless otherwise mentioned. Detection was performed 
on an Agilent Technologies LC/MSD TOF using a dual electrospray ionization (ESI) source in both 




RESULTS AND DISCUSSION: 
Extract from β- cell line (INS-1) cells was pooled and analyzed using LC-MS. Different columns 
were tested including amino-propyl HILIC, C18, C8 and C30 reversed phase columns. Different 
chromatographic conditions such as temperature and pH were evaluated to identify the best operating 
condition for analyzing different lipid classes.  
Method development for lipid analysis 
HILIC separation of lipids 
 Lipids were separated using a Phenomenex luna NH2 HILIC column, which is the same column 
used for polar metabolite analysis (26-28). Phospholipid classes were separated based on the polar 
group as described in the introduction. Most lipid classes such as phosphatidylethanolamine (PE) or 
phosphatidylglycerol (PG) were unretained and eluted very early in the chromatogram with bad peak 
shape. An exception for this was the  phosphatidylserine (PS) and phsophatidylinositol (PI) lipid classes 
which were more retained on the HILIC column than other lipids and yielded good peak shape (Figure 
‎2-4).   
 




Lipid species plotted here are (34:1), which are usually the most abundant lipid species in all 
classes. These lipid species are representative for the other lipids in their class, which will elute at nearly 
the same retention time with very similar peak shape. The ability to separate PS lipids from other lipids 
using HILIC provides several advantages. First, it is a low abundant lipid that will strongly benefit from its 
separation away from highly abundant lipids like PE or PC. Second, PS can be only synthesized from PC 
and PE (Figure ‎2-2), which are very large pools. The type of PS species formed from PE and PC cannot be 
anticipated, unlike the rest of glycerolipids species, since fatty acids are not directly connected to PS. 
Third, it can be analyzed simultaneously with polar metabolites without the need for a separate 
separation method.  
Reversed phase separation 
To investigate a better separation technique for the rest of lipid classes, we tested several 
reversed phase columns including C8, C18 and C30. The same injection volume of pooled sample was 
injected on different columns using the same LC gradient.  Peak shape for different lipid species was the 
main factor in giving cause to prefer one stationary phase than the other. The m/z values for 
representative moieties from each lipid class were used to generate extracted ion chromatograms and 
their peak shapes were investigated. INS-1 cells were incubated with palmitic acid, thus representative 
lipid species shown here mainly contain the palmitate moiety. 
C18-vs C8 column 
Xbridge BEH C18 and C8 columns (2.5 µm x 150 mm and 2 mm) were compared for their 
efficiency in lipid separation. Because the same LC gradient was applied for both columns, lipids eluted 
earlier on C8 compared to C18 (Figure ‎2-5A and B). Different lipid classes showed comparable peak 
shape between both columns (Figure ‎2-5C and D), however some lipids of interest like dipalmitoyl 
phosphatidic acid (Figure ‎2-5E and F), and tripalmitin (Figure ‎2-5G and H) showed poor peak shape on 
the C8 column that was consistent in several replicates. This might be attributable to the shorter chain 
length of C8 compared to C18, which might allow more direct (and undesirable) interaction of the lipid 





Figure ‎2-5: Chromatograms comparing C8 versus C18 column in separating different lipids species.  
 
C18 and C30 columns 
To further compare different reversed phase stationary phases, a C18 column was compared 
with a C30 column with the same dimension (3 µm x 150 mm and 2 mm).  As expected, the longer 
hydrophobic chains of C30 column increased the retention time for most lipids (Figure ‎2-6). C30 offered 
better resolution than C18 for many lipid species and allowed the separation of lipids structural isomers 
(Figure ‎2-6C-E). This is in agreement with the manufacturer brochures and other data that support the 
superiority of this stationary phase in separating lipid isomers (29). Although isomer separation is very 
useful for lipid identification, it provides more complexity to a global metabolomics study. The goal of 
global lipid profiling is to separate all lipid classes that range from highly polar such as acyl amides to the 
most non polar such as triglycerides. The outcome of using the C30 column would be a distorted peak 
shape as shown in (Figure ‎2-6C-E), unless the LC method was optimized to resolve those structural 




would result in a time consuming and impractical strategy for global lipid profiling. Bad peak shape will 
also complicate undirected analysis, where automated feature or peak selection is performed by 
software. Having shoulders in a peak will result in more errors in peak selection and improper 
quantitation.  
   
Figure ‎2-6: Chromatograms comparing C8 versus C18 columns in separating different lipid species 
As a conclusion, we showed a brief comparison between different reversed phase stationary 
phases like C18, C8 and C30 and their capabilities for separating different classes of lipids. C18 reversed 
phase stationary phase represents a reasonable-compromise chain length that enabled good separation 
of lipid classes with varying polarities. Further optimization for the chromatography conditions like pH 
and temperature using a C18 column are described in the next sections.  
Effect of temperature on lipid separation and detection using C18 column 
To investigate the effect of temperature on lipids separation, we examined two factors which 
are peak shape and lipid stability. The peak shape factor was determined by the full width at half 
maximum (FWHM) value for different lipids, while the stability of lipids was represented by the peak 
area of lipids at different temperatures. Pooled samples were injected on a C18 column at different 




temperatures (figure 7 for negative mode lipids and figure 8 for positive mode lipids). Lower 
temperature increased peak width for most investigated lipids (figures 7, 8, 9). 
        
Figure ‎2-7: Effect of temperature on the peak width of lipids ionized on negative mode MS. 
 
 




The decrease in peak width, which is also a measure of column efficiency, can be attributed to several 
factors based on the Van deemter equation :  
    
 
 
       
          
   
 
 
   
 
  
    
Where H is plate height, λ is particle shape (with regard to the packing), dp is particle diameter, 
G, ω, and R are constants, Dm is the diffusion coefficient of the mobile phase. Based on this equation, 
increasing temperature will increase the diffusion coefficient of the mobile phase which will increase the 
B term.  This is not very important in the case of high flow rate, but it will decrease the C term which will 
decrease the plate height, causing the observed improvement in peak shape and increase in column 
efficiency.  Also, at high temperature, the kinetics of secondary interactions, which are often responsible 
for peak tailing are probably accelerated, thus reducing the tailing (30). Beside the improvement of peak 
shape, increasing temperature decreased the retention time of lipids (figure 9). 
 





This decrease in retention time can be explained by Van’t Hoff equation (2):  
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Where K or k’ are the retention factor or the capacity factor respectively, G is the Gibbs free 
energy, R is the universal gas constant, T is the absolute temperature, H and S are the enthalpy and the 
entropy respectively and  Φ is the phase ratio of the system. This equation predicts that the retention 
factor is inversely proportional to temperature. This reduction in retention time is important since it 
improves the resolution, allows shortening the analytical run time and increasing the analysis 
throughput.  
The previous results showed that higher temperature was useful to obtain a good peak shape 
and faster elution of lipids; however the effect of increasing temperature on lipids stability should be 
investigated. Several lipids were quantified and representative lipids were plotted (figure 10). Lower 
temperatures caused a great variation in hydrophobic lipids, like triglycerides and DAG. This can be 
attributed to the incomplete elution of those trigylcerides at low temperatures. On the other hand, high 
temperatures like 60°C decreased the signal for the polar lyso form of lipids like LPC and LPE. This 
reduction in signal is presumably because of increased degradation of those labile species, however 
further investigation is needed for ruling out any possible reason for this decreased signal. Therefore the 
optimum temperature is ~ 45° C, which will achieve good resolution and peak shape without reducing 





Figure ‎2-10: The effect of temperature on lipid quantification. 
Effect of pH on lipid separation and detection using C18 column 
To further optimize the LC-MS method for lipid separation and detection, the effect of changing 
mobile phase pH was investigated. Ammonium hydroxide percentage in the mobile phase (A and B) was 
increased from 0.028 % to 0.2 or 0.4 %, achieving approximate pH values of 2, 4 and 8 respectively 
(figure 11C). The pH was measured in the aqueous fraction of the mobile phase before the addition of 
any organic solvent. 
Increasing the mobile phase pH reduced the signal for many lipids like sphingosine 1-phosphate and 





Figure ‎2-11: The effect of pH on lipids intensity. (A) Lipids ionized in negative mode. (B) Lipids ionized in positive mode. (C) 
pH titration curve (D) pH effect on LPA separation 
On the other hand, some lipid classes, mainly those that contain several hydroxyl groups, did 
show enhanced ionization with basic pH (figure 13) in the negative ionization mode. This was true for 




      
Figure ‎2-12:  Showing the enhancement of ionization for some lipid classes under basic pH.  
In conclusion, the choice of mobile phase temperature and pH should be carefully considered 
since both affect lipid separation and detection. A higher column temperature helped to improve the 
peak shape of lipids and shorten the LC run. However, high temperatures such as 60°C could lead to 
degradation of labile lipids such as the lyso-forms, and thus a moderate temperature should be used. 
Regarding the mobile phase pH, acidic pH provides good peak shape for all lipid classes and good signal 
intensity for the majority of lipids, thus acidic pH is the mainly used pH in most lipidomics analysis (21, 
31, 32).  However, the effect of this acidic pH in suppressing the ionization of some lipids classes such as 
PG and acylamides was not reported before. The later classes could benefit from increasing mobile 
phase pH, which will enhance their ionization but at the expense of losing some lipids like LPA. For 
global metabolomics purposes, acidic pH will be the pH of choice, unless a targeted analysis for some 







Lipids have been mainly extracted from biological tissues with a two layer method that involves 
chloroform or MTBE; however, this extraction method is not designed for the extraction of polar 
metabolites and has low throughput because it involves phase separation, drying and reconstitution. 
The goal was to investigate if a single extraction solvent for both polar and lipids could achieve 
comparable results to the specialized lipid extraction methods. The Folch method that involves 2 parts 
of chloroform and 1 part of methanol was compared to the MTBE method that replaces chloroform with 
MTBE solvent. Both methods gave comparable results (figure 13) in agreement with other published 
data (23). This was followed by comparing the MTBE method to the 1 layer extraction solvent originally 
used for polar metabolites (8:1:1 methanol: chloroform: water) (33) . Lipids were plotted in order of 
elution time; the one layer extraction solvent provided comparable results to the MTBE method in most 
lipid classes. The one layer solvent showed better results in polar lipids like LPE and S1P; on the other 
hand, hydrophobic lipids like TG showed lower extraction efficiency with this one layer extraction 
solvent. These results demonstrate the efficiency of this one layer extraction solvent for global 
metabolites extraction for adherent cells. The results also highlight the limitation of this method for the 
extraction of highly non-polar lipids.   
The ability of one layer extraction solvent to extract both polar and most non-polar metabolites 
is useful for undirected analysis and also for monitoring nutrients flux in different pathways. Undirected 
analysis requires unbiased extraction solvent that can extract most metabolites, ranging from highly 
polar to non polar metabolites. Any bias in extraction will lead to incomplete undirected metabolomics 
approach. This unbiased extraction approach was also adopted by other groups, though different 
extraction solvent was used for undirected metabolomics (26). Having one extraction solvent is 
important in during stable isotopic flux monitoring, because this will allow direct monitoring of the 
utilization of metabolites in several pathways and provide direct linkage between them. Performing the 
experiment twice for different extraction solvents might lead to incorrect replication of the same 





Figure ‎2-13: Comparing the MTBE with Folch method for lipid extraction 
 





We developed a method for comprehensive polar and non polar metabolite analysis from 
adherent cell lines. One single extraction step provided good coverage of polar metabolites (33) as well 
as different lipid classes. Highly non-polar lipids such as triglycerides will need dedicated extraction 
methods for lipids that will not be suitable for polar metabolites. We described a method for separating 
low abundant lipids such as PS simultaneously with polar metabolites using a HILIC column. We also 
optimized a method for different lipid classes’ separation using a C18 column, with a temperature of 
45°C and acidic pH as general conditions. Basic pH could be selected for specific classes such as PG and 
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Chapter 3. METABOLOME RESPONSE TO GLUCOSE IN INS-1 β-CELL 
LINE. 
This project was performed in collaboration with Dr. Mathew Lorenz.  I contributed to experiments and analysis 
related to figures (1, 2, 3, 4, 5, 7 and S1).The integrated project is presented to convey the complete project. A brief 
comparison with INS 832/3 is described in this study. 
 
INTRODUCTION  
  β-cells in islets of Langerhans secrete insulin in response to increased blood glucose. An 
acute increase in glucose evokes a rapid release of insulin which is sustained for a short period, 
designated as 1st phase, followed by an extended period of lower secretion (2nd phase). The 
metabolic pathways that facilitate 1st and 2nd phase of glucose-stimulated insulin secretion 
(GSIS) by β-cells  are not fully understood (1).  GSIS is dependent upon glucose metabolism and 
is thought to be triggered by closure of KATP channels secondary to an increase in the ATP/ADP 
ratio.  Closure of KATP channels causes membrane depolarization, opening of voltage sensitive 
Ca2+ channels, and subsequent exocytosis of a releasable pool of insulin vesicles (2).  Evidence 
supports the concept that other metabolic processes also facilitate GSIS in KATP-independent or 
amplifying pathways (3-5). A variety of metabolic coupling factors (e.g., NADPH, long-chain acyl-
CoAs, and glutamate) and pathways (e.g., pyruvate/citrate, pyruvate/isocitrate, 
pyruvate/malate, and glycerolipid/fatty acid cycling) have been implicated in both triggering 
and amplifying GSIS (3-5).  
  Measurement of metabolite changes in β-cells that correlate with GSIS has been limited 
to measuring a relatively small set of metabolites at extended time periods that cannot 
distinguish important alterations that occur in earliest phases of insulin secretion (6).  In this 
work, we employed a recently developed liquid chromatography-time of flight-mass 
spectrometry (LC-TOF-MS) method to measure signal for hundreds of metabolites in INS-1 
832/13 cells following exposure to glucose (7).  We determined the identity and levels of 87 of 
these metabolites in response to different glucose concentrations and at short intervals after 
exposure to an increase in glucose. Specific compounds monitored included metabolites 
associated with glycolysis, the pentose phosphate shunt, and the tricarboxylic acid (TCA) cycle 




of metabolites following U-[13C]glucose stimulation to assess flux through specific pathways.  
The results allowed us to confirm or modify prevailing hypotheses regarding metabolism and its 
relationship to insulin secretion and identify new pathways that may play a role in the dynamics 
of insulin secretion following glucose exposure. 
EXPERIMENTAL PROCEDURES 
Materials.  INS-1 832/13 (8) and INS-1 832/3 cells were kindly provided by Dr. 
Christopher Newgard (Sarah W. Stedman Nutrition and Metabolism Center, Duke University, 
Durham, NC).  All chemicals were purchased form Sigma-Aldrich (St. Louis, MO) unless 
otherwise noted.  HPLC grade acetonitrile was purchased from Burdick & Jackson (Muskegon, 
MI).  RPMI media, fetal bovine serum, 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
(HEPES), and penicillin-streptomycin were purchased from Invitrogen Corp, (Carlsbad, CA).   
Cell Culture.  INS-1 832/13 cells cultured in RPMI supplemented with 2 mM glutamine, 1 
mM sodium pyruvate, 10% FBS, 10 mM HEPES, 100 U/mL penicillin, 100 µg/mL streptomycin, 
250 ng/mL amphotericin B, and 50 µM β-mercaptoethanol.  Cells were plated at a density of 
~14 x 103 cells/cm2 and grown in either 6 cm or 10 cm culture dishes at 37 °C and 5% CO2 in a 
humidified atmosphere to ~70% confluence over ~5 d prior to experimentation.  Cells were 
preincubated in supplemented RPMI containing 3 mM glucose for ~20 h prior to 
experimentation. Krebs-Ringer-HEPES buffer (KRHB) was prepared containing 10 mM glucose, 
20 mM HEPES, 118 mM NaCl, 5.4 mM KCl, 2.4 mM CaCl2, 1.2 mM MgSO4, and 1.2 mM KH2PO4 
adjusted to pH 7.4 with HCl. 
Glucose Stimulation Dose Response.  Following preincubation, culture media was 
replaced with KRHB containing 0, 2, 5, 10, or 20 mM glucose + 0.2% BSA.  Cells were incubated 
for 30 min after which an aliquot of buffer was removed for insulin measurement. Metabolism 
was immediately quenched and metabolites extracted as described previously (7). 
Glucose Stimulation Time Course and Flux.  Cells were transferred to KRHB containing 
0.5 mM glucose and 0.2% BSA for 30 min prior to stimulation. Glucose was increased to 10 mM 
glucose by adding an aliquot of 1 M glucose stock.  The media was sampled for insulin 




For metabolite measurements, cells were treated as indicated above (without addition of BSA) 
and cell plates quenched from 25 to 75 min after transfer to KRHB (5 min before to 45 min after 
increasing glucose to 10 mM).  Carbon flux through glucose was also assessed by stimulating 
cells with U-[13C]glucose using the same protocol.  In some studies, cells were pretreated with 
10 mM phenylsuccinate (Sigma-Aldrich, St. Louis, MO) for 10 min to inhibit the mitochondrial 
oxoglutarate carrier (9).  
For insulin and metabolite measurements with 5-amino-1-β-D-ribofuranosyl-imidazole-
4-carboxamide riboside (AICAR) treatment, stimulation was conducted by conditioning cells in 
KRHB containing 0.5 mM glucose for 30 min and replacing the buffer with KRHB containing 10 
mM glucose with or without 25 µM AICAR.  Incubation buffer was sampled for insulin and 
plates quenched from 10 to 60 min following stimulation. 
Insulin Measurement.  Aliquots of KRHB were briefly stored on ice, centrifuged at 3000 
rpm for 3 min to pellet any suspended cells, and an aliquot of supernatant was transferred to a 
fresh vial.  Samples were stored at -20 °C and assayed using Rat/Mouse insulin ELISA Kit 
(Millipore, Billerica, MA).  Insulin secretion rate was calculated by dividing the difference in 
insulin concentration of 2 consecutive time points by the time elapsed between sampling. 
Metabolite Measurement.  Cell plates were rinsed, metabolism quenched, and 
metabolites extracted using the procedure described previously (10).  Briefly, cell plates were 
rapidly rinsed with water and quenched with liquid nitrogen.  Metabolites were extracted with 
75% 9:1 methanol:chloroform/25% water and assayed by high performance liquid 
chromatography with time-of-flight mass spectrometry (HPLC-TOF-MS).  Chromatographic 
separations were performed with an Agilent Technologies (Santa Clara, CA) 1200 HPLC system 
equipped with a Phenomenex (Torrance, CA) Luna NH2 2.0 x 150 mm, 3 µm HPLC column and a 
2.0 x 4 mm guard column using the following conditions: mobile phase A was 100% acetonitrile 
(ACN); mobile phase B was 100% 5 mM ammonium acetate pH 9.9 with ammonium hydroxide; 
gradient program was (time, %B, flow rate) 0 min, 20%, 200 µL/min, 20 min, 100%, 200 µL/min, 
20.1 min, 100%, 300 µL/min; column temperature was 35 °C; injection volume was 80 µL; 




mM, 3 um. Mobile phases and gradient were used as described (11).  DAG and PA detection 
was performed in positive and negative mode respectively.  Detection was performed on an 
Agilent Technologies LC/MSD TOF using a dual electrospray ionization (ESI) source in negative-
ion mode as described previously (10).  
Directed and undirected data processing was performed as described elsewhere (10). 
Combined peak areas are used for unresolved isomers (e.g., citrate + isocitrate and hexose 
phosphates). Several metabolites are not reported because of rapid degradation or 
interconversion. For example, pyruvate and oxaloacetate, are not reported because of rapid 
degradation of oxaloacetate to pyruvate (12).  Similarly, glyceraldehyde-3-phosphate and 
dihydroxyacetone phosphate are unstable in solution (13).   
Undirected analysis was performed by determining features (i.e., m/z signals at a given 
retention time) that changed in LC-MS peak area following a step change from 0.5 to 10 mM 
glucose for 25 min.  Features were included in the analysis that were detected in every 
chromatogram and had <40% relative standard deviation (RSD) within each group as 
determined using Agilent Technologies MassHunter Quantitative software for peak picking and 
MassProfiler Professional for data alignment and statistical analysis. These metabolites were 
identified by searching the Human Metabolome Database to match mass, analyzing isotope 
ratios, and comparing to standards when available. 
Calibration curves with standards that were available showed linear responses. To 
ensure that peak areas were linear with concentration even when analyzing a complex matrix 
of cell extract, standards for 24 analytes were spiked into an extract of INS-1 cells that had been 
incubated with 0.5 mM glucose for 2 h. Three to five concentration spikes were added to yield a 
concentration range that spanned that detected in cells and these standard addition 
experiments showed highly linear response for the majority of metabolited reported 
(Supplementary Figure S1). Residual protein was determined by Bradford Assay (14). Peak areas 
were measured from extracted ion chromatograms of [M-H]- metabolite ions with ± 70 ppm 
detection windows centered on the theoretical mass.  [M-2H]2- ions were used for acetyl-CoA 




using an identical procedure; however, values were only used to verify instrument stability and 
not used in endogenous metabolite quantification.   
Western Blot. Glucose stimulated cells were placed on ice, washed once with ice cold 
PBS and solubilized in 75 µl Laemelli's/extraction buffer (20 mM HEPES pH 7.5, 1% Triton X-100, 
-glycerophosphate, 150 mM NaCl, 10 mM NaF, 1 mM sodium orthovanadate, and 
complete protease inhibitor cocktail) from Roche Diagnostics (Indianapolis, IN).  Anti-ACC and 
anti-pACC were obtained from Cell Signaling and used at 1:1000.  Anti-HMG-CoA-reductase was 
from US Biological and was used at 2 µg/ml.  Blots were developed with ECL (Pierce, Rockford, 
IL) according to manufacturer's instructions. 
Statistics.  Data are expressed as mean ± 1 standard error of the mean (SEM).  Statistical 
significance was determined using a non-corrected two-tailed Student's t test, unpaired 
assuming equal variance or ANOVA, as appropriate. A p-value of < 0.05 was considered 
significant. 
RESULTS and DISCUSSION 
Insulin Secretion and Static Metabolite Profiles.  In these studies we employed LC-TOF-
MS to identify and quantify the levels of specific metabolites in INS-1 832/13 cells (1) following 
glucose exposure  and their relationship to insulin release.  We used U-[13C]glucose in 
secondary studies to more fully understand the dynamics of metabolite changes.      
The EC50 value for insulin secretion from INS-1 832/13 cells in response to glucose was 
6.2 mM with near maximal insulin secretion observed at ~10 mM glucose (Figure 1A), similar to 
previous reports (8).  Insulin secretion rate following a step change from 0.5 to 10 mM glucose 
showed a relatively sharp peak at ~4 min (28 ng/mg protein/ min) and a smaller broad peak 
with maxima at ~25 min corresponding to 1st phase and 2nd phase of insulin secretion (Figure 
1B, see also Figure S2 for calculation of secretion rate), consistent with previous reports of GSIS 
in islets (15) and INS-1 832/13 cells (16). Using LC-TOF-MS, a total of 1030 mass spectral 
features were detected in INS-1 832/13 cells at both 0.5 and 10 mM glucose. Following a step 
change from 0.5 to 10 mM glucose, 190 features showed statistically significant (p < 0.05) 




accurate mass search of the Human Metabolome Database, comparison of theoretical and 
observed isotopic distributions and, when available, coelution with authentic standards.   
These metabolites were quantified relative to baseline at multiple times following a step 
increase in glucose from 0.5 to 10 mM glucose (Figure 1D). We also measured the effect of 
different glucose concentrations at a single time point (25 min).  To determine if peak area 
changes were linearly related to concentration, we performed standard addition experiments 
for 24 metabolites (see Materials and Methods). As shown in Figure S1, responses were linear 
in the concentration range found suggesting that the peak area differences accurately reflect 
relative changes in concentration, thus matrix effects on ionization were low for these 
experiments. While we cannot rule out non-linear effects of matrix on some analytes, these 
results along with the observation that only a small fraction of the detected features actually 
changed with glucose, indicating a relative constant matrix, suggest that the peak areas a good 
measure of relative concentration change.  Metabolome of INS-1 832/3 was also profiled 
following a step increase in glucose from 0 till 16.6 mM (Figure 1E). Due to difference in cell 
lines some metabolites were of low levels and were not detected. However most detected 
metabolites showed similar response to glucose in both cell lines, confirming the importance of 





        Figure ‎3-1.Temporal and dose-response metabolite profiles and insulin release with glucose stimulation in INS-1 
832/13 cells and 832/3.  (A) Insulin secreted by INS-1 832/13 cells versus glucose concentration. Cells incubated in KRBH 
+0.2% BSA and 0 to 20 mM glucose for 30 min. Error bars are SEM, n = 3. (B) Insulin secretion rate versus stimulation time.  
INS-1 cells incubated in KRHB + 0.2% BSA + 0.5 mM glucose for 30 min and stimulated with 10 mM glucose for 50 min.  (C) 
Effect of 10 mM glucose treatment on LC-MS “feature” peak area. The log-log plot is for all features detected at time 0 (0.5 




detected in all replicates with RSD < 40% for either Time 0 or 25 min groups. 130 feature peak areas change >1.5 fold (shown 
outside the lines parallel to the correlation line) and are statistically different with p < 0.05.  (D) Heat maps showing 
temporal (left) and dose response (right) changes to glucose in INS-1 (832/13) metabolite levels. Levels expressed as fold 
change versus time 0.  For temporal response, cells were incubated in KRHB with 0.5 mM glucose for 30 min then stimulated 
to 10 mM glucose and sampled over 45 min. For dose response (right) INS-1 cells were incubated in KRHB + 0.2% BSA and 
treated with a step change from 0.5 to the new glucose concentration for 30 min. (E) Heat map showing temporal changes to 
glucose in INS-1 (832/3) metabolite levels. For both heat maps, asterisk indicates significant difference in peak area versus 
time 0 with p < 0.05.  
Metabolites associated with modulation of KATP Channels.  KATP channel closure 
through rise in the ATP/ADP ratio is an established trigger for GSIS.  In agreement with this 
concept, we detected a rapid increase in ATP/ADP ratio (Figure 1D and 2C) that coincided with 
1st phase insulin release. This observation matches previous reports of a several-fold increase in 
ATP/ADP in mouse β-cells that reached a maximum 1 to 3 min following glucose stimulation 
(17) and an ~2-fold increase in mouse islets within 5 min of glucose stimulation (18).  
The absolute increases in ATP concentration were <15% while both ADP and AMP fell 
markedly (Figure 1D and 2A) supporting the observations that KATP channel may be more 
influenced by reductions in ADP concentration (19) than increases in ATP. These measurements 
do not take into account the apparent rapid ATP turnover indicated by rapid rise in the level of 
phosphocreatine (Figure 1D and 2B). Phosphocreatine  has been suggested to serve as a shuttle 
for energy rich phosphate from mitochondria to plasma membrane with metabolism by KATP 
channel-associated creatine kinase to phosphorylate ADP to ATP, increasing the local ATP 
concentration (20). INS-1 832/3 cell line showed similar behavior in the increase in ATP/ADP 
ratio and phosphocreatine (Figure 2E and 2F). Although ATP level showed slight stability in INS-
1 832/13, it slightly decreased in INS-1 832/3 cell line.  The marked decrease in ADP in INS-1 
832/3 cell (figure 2D) allowed the significant rise of ATP/ADP ratio, and confirming the 






Figure ‎3-2.  Glucose stimulated time course of adenine nucleotides.  INS-1 cells were treated with 10 mM glucose and 
sampled at the indicated time points from -5 to45 min.  (A)  ATP, ADP and AMP.  (B) Phosphocreatine, (C) ATP/ADP ratios.  
Insulin secretion rate is overlaid for comparison. Error bars represent 1 SEM, n = 3 for each time point. INS-1 (832/3) cell line 








In addition to adenine nucleotides and phosphocreatine, long-chain acyl-CoAs have 
been proposed to modulate KATP activity such that decreases in concentration aid closure of KATP 
channels (21,22). Previous studies have been discordant on the actual concentration changes of 
long-chain acyl-CoAs associated with glucose stimulation (23,24).  We found an inverse dose-
response relationship of long-chain acyl-CoAs to glucose (Figure 1D). The decrease in long-chain 
acyl-CoAs was rapid and concurrent with Phase 1 GSIS, e.g. 16:0-CoA decreased ~50% within 2 
observed in 14:0, 16:1, and 18:1 CoA upon glucose stimulation with time and in glucose dose-
response profiles (Figure 1D).  This rapid decrease in long chain acyl-CoA was true also in INS-1 
832/3 cell line (Figure 1E).  
 To understand the fall in LC-CoA levels, we measured diacylglycerol and phosphatidic 
acid and found both species increase following glucose stimulation (not shown).  When INS-1 
cells were stimulated with U-[13C]glucose, there was a non-significant trend for increases in 
phosphatidic acid and diacylglycerol species (Figure 3B).  However, we did observe a significant 
and rapid rise in a M+3 phosphatidic acid (34:1) 5 and 10 minutes after glucose addition 
(p=9.4*10-4 and 2.3*10-3, respectively) and similar rises in diacylglycerol (34:1) M+3 
isotopologues (p=5.2*10-4 and 2.9*10-3, at 5 and 10 min, respectively) (Figure 3B) suggesting 
addition of 3 carbons from 13C-glycerol-3-phosphate, which is rapidly generated by glycolysis 
(Figure 3C and 3D, see below).   
These results indicate that esterification, utilizing de novo generated glycerol-3-
phosphate, facilitates removal of long chain acyl-CoAs from cytosol during the initial phase of 
glucose stimulated insulin release.  Such a decrease may be expected to aid closure of KATP 
channels, especially during first phase secretion (21,22).  In addition to modulating KATP channel 
activity, long chain acyl-CoAs may also participate in additional downstream signaling events.  
One potential route is via the malonyl-CoA/long-chain acyl-CoA pathway in which glucose 
derived acetyl-CoA is carboxylated by acetyl-CoA-carboxylase (ACC) to form malonyl-CoA. 
Malonyl-CoA inhibits carnitine palmitoyl transferase 1 (CPT1) reducing fatty acid uptake and 
causing cytosolic accumulation of long-chain acyl-CoAs (or downstream metabolites). It has 




important signaling molecules or coupling factors in secretory processes such as vesicular 
trafficking (25,26).   The metabolomic data provide a means to assess the changes expected 
from this pathway.  
After stimulation with 10 mM glucose, acetyl-CoA doubles at 2 min followed by a 
gradual decrease to levels near baseline by 5 minutes (Figure 1D and Figure 3E).  Similar 2 fold 
increase in acetyl-CoA levels was seen in INS-1 832/3 cells after 5 minutes of glucose 
stimulation that decreased to baseline by 15 minutes (figure 1E). This decrease is likely due to 
rapid turnover of acetyl-CoA as evidenced by the decrease in 12C-labled and a significant 
increase (p=3.4*10-6 and 3.5*10-7 at 5 and 10 min, respectively) in M+2 13C-labeled species 
following stimulation with U-[13C]glucose (Figure 3F).  Similarly, there is an increase in total 
(Figure 3G) and 13C-labled malonyl-CoA (p=2.3*10-5 and 5.5*10-9 at 5 and 10 min, respectively) 
(Figure 3H) with only +2 m/z increasing, suggesting a rapid carboxylation of newly formed 
acetyl-CoA, likely derived via citrate and ATP-citrate lyase (see below) (27,28).  
 We also found near complete dephosphorylation/activation of ACC, after only 2 min of 
glucose exposure (Figure 3I).  The inhibition  of CPT1 by malonyl-CoA may redirect acyl-CoAs to 
autonomous signaling events or condensation with de novo generated glycerol-3-phosphate, 
described above, to generate phosphatidic acid and diacylglycerols to participate in 
amplification of insulin secretion (29).  This rapid increase in phosphatidic acid and 
diacylglycerol suggests that the generation of diacylglycerol for amplification not only comes 
from the activation of phospholipase (see (30) for discussion), but also from rapid generation 
via esterification of fatty acids. Thus, our results support a model in which glucose derived G3P 
rapidly reacts with long-chain acyl-CoAs resulting in the removal of long chain acyl-CoAs, which, 
as pointed out above, could enhance closure of the KATP channel (21,22) while simultaneously 
generate coupling factors for GSIS. Further, the malonyl CoA production supports the supply of 
long-chain CoA for this pathway, likely in addition to that derived from phospholipase activity of 




Glycolysis.  Glycolysis, which comprises the first steps in glucose metabolism, supports 
the change in ATP/ADP ratio and closure of the KATP channel (32) and provides carbon for the 
pentose phosphate pathway (PPP) and tricarboxylic acid (TCA) cycle. 
 Hexose phosphates, comprised primarily of glucose-6-P and fructose-6-P (which are not 
resolved chromatographically) changed little over 45 min following stimulation with 10 mM 
glucose, increasing 1.2 fold over 8 min, then decreasing by 50% to ~58 µmole/mg protein 
(Figure 1D).  Dose-response studies show a 3-fold increase at 20 mM glucose (Figure 1D).  Rapid 
increase in concentrations of fructose bisphosphate, 2-phosphoglycerate with 3-
phosphoglycerate and phosphoenolpyruvate (32-, 6.7- and 5.5-fold, respectively) was observed 
following glucose stimulation (Figure 1D), suggesting that phosphofructokinase is not rate 
limiting to glycolysis in these cells. The increase in glycolytic intermediates with glucose 
stimulation was further confirmed using the INS-1 832/3 cell line. Using 16.6 mM glucose, 
glycolytic intermediates increased by at least 4 fold, confirming the previous data obtained 
from INS-832/13 cell line. 
Reoxidation of NADH to NAD+ is critical to maintaining glycolytic flux.  The formation of 
glycerol-3-phosphate from dihydroxyacetone phosphate (DHAP) by cytosolic glycerol-3-
phosphate dehydrogenase utilizes NADH to regenerate NAD+, allowing continuing flux through 
glycolysis. The proposed glycerol-3-phosphate shuttle posits a subsequent reoxidation of 
glycerol-3-phosphate to DHAP by mitochondrial glycerol-3-phosphate dehydrogenase, 
delivering NADH to the mitochondria (33).   As indicated above, glycerol-3-phosphate increased 
3.4-fold within 2 min of glucose stimulation (Figure 3C).  Stimulating cells with 10 mM U-
[13C]glucose showed that the increase in glycerol-3-phosphate is due exclusively to de novo 
synthesis over the first 10 min of stimulation, demonstrated by the significant rise in an M+3 
glycerol isotopologue  (p=1.1*10-5 and 2.2*10-6 at 5 and 10 min, respectively) (Figure 3D).  
While the high levels of the glycerol phosphate shuttle in islets has been proposed to be 
important in GSIS (34), disruption of the mitochondrial glycerol-3-phosphate dehydrogenase 
does not affect GSIS (35).  Our finding that there is a rapid esterification of fatty acids with de 




signaling intermediates, the esterification may also play a role in regeneration of cytosolic 
NAD+, enhancing glycolytic flux, thus maintaining a high ATP/ADP ratio.   
 
 
Figure ‎3-3.Changes in metabolites associated with the malonyl-CoA mechanism of insulin secretion.  Time dependent 
changes in the relative concentration of 16:0 acyl-CoA (A), glycerol-3-phosphate (C), acetyl-CoA (E) and malonyl-CoA (G) 
levels following stimulation with 10 mM glucose in INS-1 cells.  Changes in total mass and 13C-labeled  isotopologues of 
phosphatidic acid (B), glycerol-3-phosphate (D), acetyl-CoA (F) and malonyl-CoA (H) following stimulation with 10 mM U-
[13C]glucose.  Error bars represent 1 SEM, n = 3. (I) Levels of pACC at baseline and following stimulation of INS1 cells with 10 
mM glucose for 2 or 25 min.  p-values are given for total pool size on the graph.  p-values for isotopologue analysis are 




TCA cycle and anaplerotic shuttles.  Metabolites in the TCA cycle participate in 
pathways that generate metabolites and cofactors which play a role in augmenting GSIS (3-5).  
The β-cell can increase TCA intermediates from pyruvate through pyruvate dehydrogenase and 
pyruvate carboxylase (36) and through additional anaplerotic reactions  (37).  As shown above, 
acetyl-CoA increased 1.5-fold within 2 min of stimulation and returned to prestimulation 
concentration within 12 min of glucose addition.  Span 1 intermediates citrate + isocitrate 
(Figures 1D, 4A) and α-ketoglutarate (Figure 1D) increased 3- to 4-fold while, succinyl-CoA, and 
succinate showed much smaller absolute changes (Figure 1D).  The Span 2 metabolite malate, 
increased ~30-fold after glucose stimulation (Figures 1D and 4B). 
To assess the mechanisms of change in TCA cycle metabolites, we measured their 
isotopic enrichment over the initial 10 min of exposure to 10 mM U-[13C]glucose.  Acetyl-CoA is 
generated primarily from glucose as the M+2 isotopologue contributes to the majority of the de 
novo accumulated acetyl-CoA (p=3.4*10-6 and 3.5*10-6, at 5 and 10 min, respectively) (Figures 
3E and 3F) and is accompanied by a ~40% rise in citrate/isocitrate, from 20 nmol/mg protein to 
28 nmol/mg protein at 5 and 10 min (Figure 4D).  Approximately 90% of the increase in citrate 
mass was contributed by the M+2 isotopologue of citrate/isocitrate (p=3.0*10-6) (Figure 4D).  
The labeled pool continued to increase and after 10 min, the majority of the label as M+2 and 
less than 3% as M+3 or M+4 citrate/isocitrate. Thus, while total citrate/isocitrate levels rise 
slowly during the initial phases of insulin secretion, there is rapid turnover, with new 
citrate/isocitrate derived largely from pyruvate dehydrogenase (PDH) generated M+2 
[13C]acetyl-CoA.  The minimal increase in M+3 and M+4 isotopologues of citrate/isocitrate 
suggest that the majority of citrate/isocitrate exits the TCA cycle with minimal ‘turns’, at least in 
the early stages of GSIS.   
Only a small percentage of glutamate is labeled with 13C in the first 10 min following 
glucose exposure (Figure 4F). Importantly, there is a significant (p < 0.04) decrease in 12C-
glutamate, about ~20% of the pool, suggesting minimal anaplerotic flux into glutamate.    
Mitochondrial-derived glutamate has been proposed to participate in GSIS, in part through 
rapid accumulation of glutamate within the insulin secretory granules (38). While our data 




intracellular glutamate during GSIS (40).  We cannot rule out that the reduction in glutamate is 
due to uptake and subsequent release to the medium via secretory granules. And as a 
confirmation for the previous data, INS-1 832/3 showed also a reduction in glutamate with 
glucose stimulation (Figure 1E). 
Although oxaloacetate could not be accurately measured because of its instability, we 
found a ~3-fold increase in malate after 5 min and 4.8-fold after 10 min (Figure 1D and 4B). A 
novel finding is that in cells exposed to 16.7 mM U-[13C]glucose, the observed increase in 
malate was largely accounted for by accumulation of 12C-malate, increasing the estimated 
concentration from 12 nmol/mg protein to 70 nmol/mg at 10 min, with only about 15% of the 
increase in mass due to de novo entry of 13C-label into malate (Figure 4E).  About 60% of this de 
novo derived 13C-malate is the M+3 isotopologue and ~40% M+2 (Figure 4E), suggesting near-
equal generation from pyruvate carboxylase (M+3) and TCA cycle (M+2).  The source of the 
‘unlabeled’ malate is likely the relatively large pool of aspartate (via oxaloacetate). At 10 min, 
malate levels continue to rise and aspartate levels are restored to near baseline levels, with the 
increase due to accumulation of M+2 and M+3 isotopologues of aspartate in a similar 
proportion to that found in malate (Figure 4G).  This finding is consistent with a partial 
operation of the ‘malate-aspartate shuttle’, though we propose that the influx of aspartate is 
operating to provide anaplerotic oxaloacetate/malate to the TCA cycle and the transfer of 
NADH to the interior of the mitochondria.  A previous study (41) provided evidence that a 
decrease in aspartate was correlated with GSIS, and provided anaplerotic substrates to the TCA 
cycle.  However, based on the isotopic labeling observed, our findings do not support the 
contention that the aspartate is derived from glucose or is in a separate metabolic pool from 
malate, as suggested elsewhere (41).    
These results also do not support a robust activity of the pyruvate shuttle (1,42,43) to 
generate oxaloacetate/malate, at least in the earliest time points of insulin secretion.  If the 
pyruvate shuttle were responsible for the rise in malate, then decarboxylation of citrate would 
be expected to give rise to equal amounts of M+2 and ‘unlabled’ malate and, with the 




The observed transient decrease in α-ketoglutarate concentrations in early time points 
following the addition of glucose (Figure 1D) may be due to the transamination of α-
ketoglutarate from aspartate to generate glutamate and oxaloacetate, with the latter 
subsequently reduced to malate, allowing the transfer of the glycolytically derived NADH to the 
mitochondria (see Figure 7 for schematic).  The glutamate can be converted back to α-
ketoglutarate through glutamate dehydrogenase, with the generation of NAD(P)H and NH4+.  
To further support the role of the malate-aspartate shuttle in the rise in malate we 
pretreated INS-1 cells with phenylsuccinate, which inhibits the oxoglutarate carrier, to reduce 
efflux of α-ketoglutarate and entry of malate into the mitochondria (9).  Pretreatment with 
phenylsuccinate did not impair reduction in AMP levels (Figure 4H) or reduction in NAD+/NADH 
ratio (Figure 4H and 4I) following glucose stimulation.   The rise in citrate (Figure 4J) was 
blunted and glutamate levels fell (Figure 4K) following phenylsuccinate treatment and this was 
largely due to changes in the levels of 12C-labeled isotopologues.   There was a marked and 
significant reduction in the rise in malate following phenylsuccinate treatment (Figure 4L), 
primarily in the 12C-label isotopologue.  We suggest that the fall in malate is due to 
consumption of mitochondrial malate without replenishment by cytosolic malate.  Aspartate 
levels are likewise reduced by phenylsuccinate treatment and, as with malate, the 13C-
isotopologue distribution is not changed (Figure 4M).   
As inhibition of the oxoglutarate carrier inhibits glucose-induced insulin release (44), 
these data further confirm that malate-supported anaplerosis and/or shuttling of reducing 
equivalents by malate into the mitochondria are critical to sustaining insulin secretion. The 
observed rapid increase in malate can also clarify data by Lu et al. (39) who, through modeling 
of NMR-derived spectra of INS-1 cells extracts, proposed the presence of two distinct pools of 
pyruvate that enter into the Krebs cycle following glucose stimulation of β-cells, one derived 
from glycolysis and the other from a non-glycolytically derived pool.  We believe our finding of a 
rapid rise in malate derived from a non-glucose source could, via cytosolic malic enzyme, 
generate pyruvate, giving rise to the ‘second’ pool of pyruvate.  Alternatively, the labeling 
pattern of highly glucose-responsive INS-1 cells lines presented by Lu et al, may be explained by 




result in a relative ‘dilution’ of the glutamate pool.  We favor the latter explanation as 
phenylsuccinate treatment results in a significant reduction in the 12C-isotopologue 
concentration of glutamate with minimal change in the M+2 13C-isotopologue levels, 
presumably derived from PDH derived M+2 13C-acetylCoA (Figure 4K).         
 
Figure ‎3-4.Temporal changes of TCA cycle and related metabolites following addition of 10 mM glucose to INS-1 cells.  A-D. 
Changes in the relative concentration of citrate/isocitrate (A), malate (B) and NADPH/NADP+ ratio (C).  D-E.  Changes in total 
mass and 13C-labeled isotopologues of Citrate/isocitrate (D), Malate (E), Glutamate (F) and Aspartate (G) following 
stimulation with 10 mM U-[13C]glucose.  H-N. Effect of phenylsuccinate on metabolite levels.  Cells were preincubated 
without or with 10 mM phenylsuccinate for10 min prior to addition of 10 mM glucose.  Total metabolite concentration of 
AMP (H) and NAD/NADH ratio (I) and changes in relative concentration of 13C-labeled isotopologues  of citrate/isocitrate 
(D), malate (K), glutamate (L) and aspartate (M) Error bars represent 1 SD, n = 3.  Note 3, 4 and 5 13C-containing 
isotopologues of glutamate were obscured by presumptive breakdown products of phenylsuccinate.  p-values for 




NADPH.  NADPH has been cited as a critical metabolite for GSIS.  NADPH increased 
slightly (1.3-fold) but insignificantly over ~12 min of glucose stimulation which is similar in 
magnitude to changes reported in islets (45) (Figure 1D).  The NADPH/NADP+ ratio increased 
abruptly after addition of glucose and increased 5.8 fold over 25 min, correlating well with 1st 
and 2nd phase insulin secretion (Figure 1D and 4C).  It has been proposed that cycling of 
metabolites from mitochondria to the cytosol, via citrate, isocitrate or malate to pyruvate 
results in generation of cytosolic metabolites and/or NADPH which participate in GSIS (1,42). 
The relatively rapid rise in M+2 malonyl-CoA isotopologue (Figure 3H), suggests a significant flux 
of citrate from the mitochondria which generates M+2 acetyl-CoA (Figure 3F) serving as a 
substrate for ACC via ATP-citrate lyase (46).  This efflux of citrate/isocitrate, can generate 
NADPH by the conversion of isocitrate to α-ketoglutarate in the cytosol.  In addition to the 
proposed generation of NADPH from α-ketoglutarate in the cytosol due to the malate-aspartate 
shuttle-mediated influx of aspartate (see above), could be primary sources of NADPH, 
augmenting GSIS. In INS-1 832/3, NADPH increased significantly upon glucose stimulation, on 
the other hand, NADP+ decreased significantly. The higher changes in those metabolites 
compared to INS-1 832/13 cell line might explain the improved glucose responsiveness of INS-1 
832/3 cell line (62).   
Succinate and short chain fatty acids.  Succinate has been proposed as a key metabolite 
that participates in the generation of molecules that can act as second messengers for 
potentiation of insulin secretion (43) including short chain fatty acids, acetoacetate, malonyl-
CoA and 3-hydroxy-3-methyl-glutaryl-CoA (HMG-CoA) (43,47).  Following glucose exposure, we 
found a rapid increase in succinate levels (Figure 1D and 5A) and malonyl-CoA (Figure 1D and 
3H) in the INS-1 832/13 cells.  In contrast we found a significant reduction in HMG-CoA (Figure 
1D and 5B), similar to previous reports (48).  The reduction in HMG-CoA levels appears to be 
due to rapid consumption as cells incubated for 5 or 10 min with U-[13C]glucose showed a rapid 
decrease in fully 12C-labeled HMG-CoA isotopologue and an increase in various 13C-labeled 
isotopologues suggesting de novo synthesis that cannot keep up with consumption (Figure 5D). 




we do not observe a change in the phosphorylation state of HMG-CoA reductase following 
glucose stimulation of INS-1 832/13 cells (Figure 5E).   
Farnesyl pyrophosphate, a downstream product of the HMG-CoA pathway involved in 
isoprenylation of proteins (49), was found to increase rapidly following glucose stimulation 
(Figure 5C) in a time course that mirrors that of the fall in HMG-CoA and 1st phase insulin 
secretion.    Recent studies have suggested that specific small G-proteins (Cdc42 and Rac1) play 
an important role in GSIS (50,51). These signaling proteins undergo prenylation at their C-
terminal cysteine residues which is essential for the transport and fusion of insulin-containing 
secretory granules with the plasma membrane and the exocytosis of insulin which has been 
implicated in GSIS (50). The rapid increase in substrate for isoprenylation, farnesyl 
pyrophosphate, suggests that such modifications can occur in a time frame to be relevant for 1st 
phase insulin secretion. Further, the dramatic reduction in HMG-CoA suggests that it may 
become limiting to flux through this pathway and therefore limiting GSIS.  
INS-1 (832/3) cell line showed similar decrease in HMG-CoA and increase in FPP upon 
glucose stimulation (figure 1E) confirming the higher glucose flux through the mevalonate 
pathway during GSIS. However, succinate showed different response compared to INS-1 
(832/13), where it decreased after glucose stimulation. This decrease can be attributed to the 





Figure ‎3-5.Metabolites participating in the succinate mechanism of glucose stimulated insulin secretion. A-C.  Time-
dependent changes in Succinate (A), HMG-CoA (B) and farnesyl pyrophosphate (C).  D. Changes in total mass and 13C-labeled  
isotopologues of HMG-CoA following stimulation with 10 mM U-[13C]glucose.   Error bars represent 1 SEM, n = 3. E. 
Phosphorylated HMG-CoA reductase at baseline and following stimulation with glucose for 2 or 25 min. p-values for 
isotopologue analysis are indicated in the text 
Pentose Phosphate Pathway (PPP) derived metabolites.  Metabolites in the PPP are not 
often measured in investigations of GSIS but play a key part in cellular metabolism by supplying 
5-carbon substrates for purine, pyrimidine, and histidine synthesis and generating NADPH for 
lipid biosynthetic pathways. However, the PPP is not highly active in β-cells and likely 
contributes little to the generation of NADPH (42).  We observed that most PPP metabolites 
increased in parallel to increasing glucose concentration (Figure 1A and B). Rapid and 
substantial relative increases in the pentose phosphate pathway metabolites pentose 
phosphates, 6-phosphogluconate, sedoheptulose phosphates and phosphoribosyl 
pyrophosphate (1.8-, 3.2-, 2.4-, and 7.4- fold increases, respectively) were observed. Significant 
labeling of 6-phosphogluconate following stimulation of cells with U–[13C]glucose was observed 
(not shown), indicating direct flux into the PPP.    Although large relative increases in PPP 
metabolite levels with glucose stimulation are detected, the pool size of these metabolites is 




of glucose carbon enters the TCA cycle and does not enter the PPP (52) and a relative 
unimportance for this pathway in the generation of NADPH in supporting GSIS.   
ZMP is an endogenous metabolite in the purine synthesis pathway and a precursor to 
IMP.  Although measurements of endogenous ZMP levels have not been reported in β-cells, we 
detected a 9-fold increase to ~4.0 μmole/mg protein that reached a maximum ~25 min after 
glucose stimulation (Figure 1D and 6A).  Supporting an increase by de novo biogenesis as 
opposed to stabilization of ZMP, we found that both phosphoribosyl pyrophosphate which links 
the PPP to the nucleotide synthesis pathway and glycinamide ribotide, a ZMP precursor, were 
also detected and increased both temporally and in a dose-response manner after addition of 
glucose (Figure 1D and 6A, B).  This was true also in INS-1 832/3 cell line, where all pentose 
phosphate pathway metabolites as well as ZMP increased significantly after glucose stimulation 
(figure 1E). 
ZMP can substitute for AMP in enhancing phosphorylation and activation of AMP-
activated protein kinase (AMPK), an important regulator of cellular energy balance (53). Indeed, 
AICA riboside (AICAR), which is phosphorylated in cells to generate ZMP, is widely used to 
activate AMPK.  Acute exposure to AICAR has been found to both decrease (54,55) and 
potentiate insulin release (56).   Based on the timing of the increase in endogenous ZMP found 
in our studies, we hypothesized that it may serve as a negative regulator of GSIS during the 
second phase of insulin release.  To test this idea, we treated INS-1 832/13 cells with 10 mM 
glucose and 25 µM AICAR and achieved ~4x higher intracellular ZMP levels at 40 min relative to 
control cells stimulated with 10 mM glucose only (Figure 6C).  This increase in ZMP was 
accompanied by 20% reduction in rate of insulin release 40 to 60 min post glucose stimulation 
(Figure 6D).   Although ZMP increases, there was no evidence of activation of AMPK as no 
change was seen in the phosphorylation of HMG-CoA reductase and a decrease in ACC-1 
phosphorylation was observed following glucose addition (Figure 3I).  Therefore, while ZMP 
may restrain GSIS, at endogenous levels this effect does not seem to be through AMPK; perhaps 






Figure ‎3-6. Formation and effect of ZMP in INS-1 cells.  A and B.  Time (A) and concentration-dependent (B) changes in purine 
metabolic pathway in INS-1 cells stimulated with glucose.  PRPP = Phosphoribosylpyrophosphate, GAR =  glycinamide 
ribotide, ZMP = 5-amino-4-imidazolecarboxamide ribotide.  (C) Time-dependent formation of ZMP in INS-1 cells stimulated 
with 10 mM glucose with or without 25 µM AICAR. Error bars represent 1 SEM, n = 3.  (D)  insulin secretion rate measured by 
change in incubation buffer insulin concentration over indicated time period.  Error bars represent 1 SEM, n = 8.  Asterisk 
indicates significant difference in insulin release rate with p < 0.05. 
Sugar Nucleotide Donors.  We detected 8 common sugar nucleotide donors with GDP-
mannose changing the most substantially (Figure 1D).  GDP-mannose forms from conversion of 
glycolytic intermediate fructose-6-phosphate to mannose-6-phosphate and mannose-1-
phosphate before condensing with GTP (58).  This metabolite has not previously been 
quantified in β-cells; but, we observe a rapid increase that peaked at 14-fold over basal (~4.2 
μmole/mg protein) within 8 min of glucose followed by a gradual decrease.  GDP-fucose, a 
product of GDP-mannose metabolism (59), was unchanged.  While determination of these 
metabolites in β-cells have not been previously explored, we have previously described that 




IGF-II results in augmentation of insulin secretion, even at low concentrations of glucose (60).  
The binding of mannose-6-phosphate-tagged proteins may play a regulatory role in insulin 
secretion by interaction with insulin secretory vesicles.   
Additional metabolites.   In these studies, we identified additional metabolites that 
showed dynamic changes following glucose exposure in INS-1 (832/13). In addition to 
adenosine, other mono- and diphosphonucleotides decreased by 1.7-4.3 fold within 2 min of 
glucose stimulation.  GTP increased only slightly (< 5%) whereas UTP and CTP increased 40% 
and 80%, respectively with reciprocal falls in their mono and dinucleotides (Figure 1D).  These 
results were different in Ins-1 832/3 cells, were GTP and UTP slightly decreased with glucose 
stimulation, while CTP did not change. Recent studies have provided evidence for a significant 
role for mitochondrial GTP in GSIS (61).  While GTP levels do not change significantly, the pool 
of mitochondrial GTP is small compared to the cytosolic pool, thus changes in the mitochondrial 
pool may not be detectable.  
We also observed decreases in pantothenic acid with glucose in both cell lines.  As this 
metabolite is important for CoA synthesis, its decrease may reflect consumption in de novo 
production of CoAs.  Besides long-chain acyl-CoAs and farnesyl pyrophosphate discussed above, 
we also found changes in other compounds involved in lipid metabolism including decreases in 
free fatty acids and citicolline, an intermediate in production of phosphatidylcholine. Citicolline 
or CDP-choline and CDP-ethanolamine decreased upon glucose stimulation in INS-1 832/3 cell 
as well. This decrease seen in both cell lines is presumably due to the denovo-lipogenesis that 
consume those intermediates to form PC and PE respectively.  While investigation of all these 
pathways is beyond the scope of this paper, these results indicate that this analytical method 






Figure ‎3-7. Schematic of metabolite levels and 13C enrichment of indicated metabolites at baseline and after 5 and 10 min 
exposure to 10 mM glucose.  The size of each circle denotes the relative concentration of that metabolite, but does not 
reflect the relative concentration among the metabolites.  13C isotopologue percentage is indicated by the gradation of the 
pie and includes the baseline natural enrichment of 13C of ~1%.  Grey circles indicate that the isotopic enrichment was not 
determined for those metabolites. 
 
Conclusions.  The use of LC-TOF-MS has allowed us to measure the temporal and 
dose response to increasing glucose concentration for a wide range of metabolites in INS-1 
832/13 cells.  By combining static (Figure 1) measurements and flux analysis (Figures 3-5) we 
have confirmed, extended or proposed modifications to several prevailing hypotheses 
regarding the metabolic pathways associated with GSIS (Figure 7). The simultaneous 




acyl-CoAs and other intermediates show a novel interaction of metabolites.  Novel findings 
include: 1.  rapid esterification of long chain acyl-CoA with de novo synthesized glycerol-3-
phosphate which explains the rapid fall in acyl-CoAs, allowing enhanced closure of the KATP 
channel and generation of phosphatidic acid and diacylglycerols to act as possible second 
messengers. 2.  Rapid turnover of Span 1 TCA metabolites and rapid increases in the Span 2 
metabolite, malate, which increases primarily by influx of malate into the mitochondria.  3.  
Rapid generation of malonyl-CoA from citrate coincident with a glucose-induced 
dephosphorylation of ACC1.  4.  Significant flux of glucose-derived carbon into HMG-CoA and a 
rapid depletion of this metabolite with a parallel, rapid rise in farnesyl pyrophosphate, 
providing substrate for isoprenylation of proteins.  5.  De novo synthesis of ZMP from glucose 
entering the pentose phosphate pathway which may modulate insulin release. 6.  Increases in 
sugar nucelotides, including GDP-mannose, which may provide substrate for modification of 
proteins important for secretion.     
These studies are limited to the glucose-responsive INS1 (832/13) cells but most findings 
were also reproduced in another glucose responsive cell line INS-1 (832/3).  The studies 
presented here provide several hypotheses for metabolic pathways that may play varying roles 
in the augmentation of GSIS which can be tested in additional experiments in both INS-1 cells 
and in isolated isles.  Assessing the alterations of specific metabolites in response to high 
glucose or fatty acid exposure may also provide information as to how chronic insulin resistance 
associated with obesity may result in altered β-cell metabolism which may lead to altered 
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 Supplmentary information 
 
Figure S1. Results from standard addition experiment to determine linearity of response for 24 metabolites. An extract of 
INS-1 cells that had been incubated for 2 h in 0.5 mM glucose in KRB was divided into aliquots. The aliquots were spiked to 
create different concentrations of 24 metabolites and a constant final volume of extract. Each sample was analyzed by LC-
TOF-MS and peak areas related to the spiked concentration (i.e., does not incorporate endogenous concentration). Analytes 
that have a smaller number of points in the lines have high concentrations so low concentration spikes were not used 




Chapter 4. METABOLIC REMODELING BY FATTY ACIDS AND 
ENHANCEMENT BY FFAR1/GPR40 AGONISTS DURING 
POTENTIATION OF INSULIN SECRETION 
ABSTRACT 
Acute fatty acid (FA) exposure potentiates GSIS in β-cells through metabolic and 
receptor mediated effects.  We assessed the effect of fatty acids on the dynamics of the 
metabolome in INS-1 (832/3) cells following exposure to U-[13C]glucose to assess flux through 
metabolic pathways.  Metabolite profiling showed a fatty acid-induced increase in acyl-CoAs 
which were rapidly esterified with glucose-derived glycerol-3-phosphate to form  
lysophosphatidic acid, mono- and diacylglycerols and other glycerolipids, some implicated in 
augmenting insulin secretion.  Glycolytic flux increased along with a reduction in the 
NADH/NAD+ ratio, presumably by an increase in conversion of dihydoxyacetone phosphate to 
glycerol-3-phosphate.  The fatty acid-induced increase in glycolysis also resulted in increases in 
tricarboxylic cycle flux and oxygen consumption.  Inhibition of fatty acid activation of 
FFAR1/GPR40 by antagonist or siRNA knockdown decreased glycerolipid formation, attenuated 
fatty acid increases in glucose oxidation, and increased mitochondrial FA flux as evidenced by 
increased acyl-carnitine levels.  Conversely, FFAR1/GPR40 activation in the presence of low FA, 
increased flux into glycerolipids and enhanced glucose oxidation.  These results suggest that by 
remodeling glucose and lipid metabolism, fatty acid significantly increases the formation of 
both lipid- and TCA cycle-derived factors that augment insulin secretion.    
INTRODUCTION 
Glucose stimulated insulin secretion (GSIS) is mediated by a series of events that depend 
upon increases in glycolytic and tricarboxylic cycle (TCA) flux and the generation of metabolic 
coupling factors (1).  Glycolytically derived ATP likely plays a role on the closure of KATP channels 
during the early phase of insulin secretion (1) and efficient glycolysis is dependent upon 
regeneration of NAD+, at least in part via malate-aspartate and glycerol-3-phosphate shuttles 
(2).  The TCA cycle is thought to participate in substrate cycling which allows the generation of 
NADPH and other proposed intermediates which participate in augmentation of insulin 




Free fatty acids play an important role in regulating β-cell function under physiological and 
pathological conditions.  Exposure to fatty acid is known to amplify glucose stimulated insulin 
secretion (GSIS) with optimal potentiation dependent upon both fatty acid metabolism within 
the β-cell (4, 5) and activation of the FFAR1/GPR40 receptor. Activation of this surface G protein 
coupled receptor has been shown to be responsible for ~ 50% of fatty acid potentiation effect 
of the second phase of GSIS in rat islets (6, 7).   Both lipogenesis and lipolysis generate 
glycerolipids, such as DAG, which provides additional signals for potentiating GSIS (8).   Fatty 
acids must be esterified to acyl-CoAs to function in GSIS potentiation; inhibition of lipogenesis 
by triascin C, an acyl-CoA synthase inhibitor, inhibited FFA potentiation of insulin secretion in 
rat islets (9). Long chain acyl-CoA can act as a lipid signal for insulin exocytosis (10, 11), increase 
intracellular free calcium, and modulate KATP (12) and calcium channels (13).  Increased 
formation of malonyl-CoA via mitochondrial derived citrate reduces fatty acid oxidation and 
enhances lipogenesis (5), increasing the availability of acyl-CoAs for metabolism.  In addition, 
inhibition of lipase decreased phase 2 insulin secretion in rat islets (14), indicating a role for 
lipolysis in potentiation of insulin secretion.  The decrease was reversed by palmitic acid, 
suggesting that lipolysis can be substituted by de novo generation of signaling lipids.  
To our knowledge, there are no large scale assessments of metabolite changes in 
response to acute fatty acid exposure in β-cells.  In previous papers (15, 16), we have shown 
that assessment of metabolites in INS-1 cells, a robust model for studying GSIS, can provide 
detailed temporal and assessments of flux through multiple metabolic pathways.  Using these 
techniques we assessed the changes in the INS -1 cell metabolome associated with fatty acid 
potentiation of GSIS. In addition to temporal changes in metabolites, we used both U-
[13C]glucose and U-[13C]palmitate to follow remodeling of INS -1 cell metabolism in response to 
fatty acids and to synthetic FFAR1/GPR40 agonists and antagonists.   The studies suggest that 
fatty acids enhance the flux of dihydroxyacetone phosphate to glycerol-3-phosphate, 
regenerating NAD+, resulting in enhanced glycolytic and TCA cycle flux.  We also provide 
evidence that FFAR1/GPR40 signaling enhances this flux, providing additional mechanisms for 





Materials.  INS-1 832/3 cells (hereafter, INS-1) were kindly provided by Dr. Christopher 
Newgard (Duke University). All chemicals were purchased from Sigma-Aldrich unless otherwise 
noted.  
Cell Culture and media.  INS-1 cells were cultured in RPMI as described previously (16). 
Cells were incubated in RPMI supplemented with 3 mM glucose for ~6 h prior to 
experimentation. Free fatty acid solution was prepared by finely grinding fatty acid (sodium 
palmitate) using mortar and pestle and adding it to a warm solution of BSA (fatty acid free) 
dissolved in KRHB buffer (16). Leaving the palmitate solution to stir using magnetic stirrer for 
several hours at high speed yielded a homogenous suspension.   
Glucose Stimulation.  Palmitic or oleic acid (0.5 mM) was complexed with 0.5 % BSA 
(fatty acid free) solution in KRHB to achieve a 1:6 molar ratio of BSA to fatty acid. Cells were 
incubated for 30 min in glucose-free media with BSA or palmitate or oleate before stimulation 
with 16.6 mM [12C] glucose or U-[13C] glucose for time periods ranging from 5 to 60 minutes.  At 
each time point, cells were snap frozen using liquid nitrogen and kept at -80° C until metabolite 
extraction as described previously (15).  At each time point the media was also collected for 
insulin measurement.  
Fatty acid metabolism. Cells were incubated with 500 μM U-13C palmitic acid (Sigma), 
500 μM U-13C oleic acid (sigma) or 0.5 % BSA (fatty acid free) for 30 min in KRHB with 0 mM 
glucose before stimulation with 16.7 mM 12C-glucose for 60 min.  
GPR40 activation and inhibition.  Cells were incubated for 30 min with or without 
palmitate in the presence of either the FFAR1/GPR40 antagonist GW1100 (5 μM) or the 
FFAR1/GPR40 agonist Cay 10587 (10 μM) (Cayman Chemical, Ann Arbor, MI). Drugs were 
dissolved in DMSO which was added alone for control studies.   
GPR40 Knockdown.  INS-1 cells were cultured in 6 well plates and 150 pM of GPR40 
siRNA (Invitrogen) or Non-targeting siRNA (Thermo) was added for48 hours cells after which 
cells were harvested for Western blot or for metabolomic profiles.  
Oxygen consumption and extracellular acidification rate measurement.  Measurements were 
performed using a Seahorse XF24 extracellular flux analyzer (Seahorse Bioscience) using 5x KHB 




Na2HPO4). Briefly cells were seeded in 24 sea horse plate in full RPMI.  RPMI was replaced with 
low glucose RPMI 6 hours before the experiment. The cells were incubated at 37 C in the 
absence of CO2 for 1 hr after which media was changed to KHB containing fatty acid or BSA 
before assay. After equilibration, measurements were taken for 10 minutes followed by the 
addition of 16.7 mM glucose for an additional 40 min for assessment of oxygen consumption. 
Insulin measurement and Western blot.  For insulin assay, a 100 µl aliquot of supernatant was 
assayed using a rat/mouse insulin ELISA kit (Millipore, Billerica, MA) after dilution with 1% BSA.  
Western blot for phospho-ACC, phospho-AMPK or β-actin (all from Cell Signaling, Danvers, MA) 
or GPR40 receptor (Novus Biologicals, Littleton, CO) was performed as described (16). 
Metabolites Measurement.  Metabolites were extracted using 90% (9:1 methanol: 
chloroform)/10% water. Polar metabolites were separated using Luna NH2, and lipids 
separated using Xbridge BEH C18 XP or Capcell C18 column (2 mm x 150 mm).  Metabolites 
were detected by time of flight mass spectrometry in negative and positive mode as described 
previously (16). Untargeted analysis was performed using XCMS online (19) and metabolites 
were identified using accurate mass or authentic standards (if available) (16). Relative peak 
areas were used for relative quantification of identified metabolites (16).   
Statistics.  Data are expressed as mean ± 1 standard error (S.E). Statistical significance was 
determined when appropriate using unpaired, two-tailed Student's t test assuming equal 




Palmitic acid potentiates glucose stimulated insulin secretion (GSIS).  INS-1 cells were 
preincubated with BSA or 500 µM palmitate complexed to BSA (‘palmitate’) for 30 min in 0 mM 
glucose followed by stimulation with 16.6 mM glucose.  Media was collected for measurement 
of insulin secretion from 0 to 60 min after addition of glucose. Cell extracts were collected for 
determination of 69 metabolites by LC-MS prior to addition of BSA or palmitate (-30 min) or 
from the same cultures used to assess insulin secretion (0 to 60 min) (Figure 1).  As previously 




fold, at each time point compared to BSA controls (Figure 2A).  Heat maps of metabolite 
profiles (Figure 1) showed that 30 min of preincubation with either BSA or palmitate in glucose-
free media resulted in lowering of the concentrations of most metabolites relative to 
preincubation levels with the exception of expected rises in nucleotide monophosphate levels.    
 
As we (16) and others (20) have previously observed, palmitoyl-CoA rapidly decreased (~ 
50%) following the addition of glucose in both BSA and palmitate pretreated cells (Figure 2B).   
This observation is despite the marked increase in palmitoyl-CoA concentration following 
preincubation with palmitate (Figure 2B).  In addition, the concentration of palmitoyl-carnitine 
rapidly declined (Figure 2C), likely representing reduction in entry of palmitate into the 
mitochondria.  The reduction in fatty acid entry into the mitochondria in β-cells has been 
ascribed to elevations in malonyl-CoA which inhibits CPT1 activity on the outer mitochondrial 
membrane (for review, see (21)).  Indeed, in the absence of fatty acids, malonyl-CoA levels 
increase following glucose addition to INS-1 cells.  However, in the presence of palmitate, the 





Figure ‎4-1. Temporal metabolites profile of INS-1/832/3 cells upon glucose stimulation in the presence or absence of palmitic 
acid. The heat map (middle and right) are showing the metabolites levels expressed as fold change of the (-30 min) time 
point. INS-1 cells were incubated in RPMI with 3 mM glucose for 6 hours (-30 time point) before incubation in KRHB for 30 
minutes with no glucose in the presence or absence of 500 µM palmitate (0 time point). Cells were stimulated with 12C 




0.05.  The heat map to the left is showing the fold change for metabolites in palmitate versus BSA treated cells, comparing 
each time point. Asterisk indicates significant difference in peak area of each time point of palmitate versus the 
corresponding BSA treated cell with p < 0.05. Statistics test used was ANOVA using Tukey’s post-hoc analysis using SPSS 
software. 
 
Figure ‎4-2.Palmitic acid incubation effect on GSIS, AMPK and related metabolites. Insulin levels after stimulation with 16.6 
mM glucose for different time intervals in the presence or absence of 500 uM palmitate (A). Levels of palmitoyl-CoA (B) 
Palmitoyl-carnitine (C) Malonyl-CoA (D) AMP (G) ZMP (H) before and after 30 min incubation with 500 µM palmitate (time 
zero) and after stimulation with 16.6 mM glucose for different time points. Western blot for pAMPK (E) and pACC (F) before 
glucose addition (time zero) and after 30 min of glucose stimulation (30 min). * = p < 0.05 between BSA and palmitate at 
each time point.  Error bars represent 1 S.E n= 3-4 per time point. 
 
AMP-activated protein kinase (AMPK) is a known regulator the glycerolipids/free fatty 




(ACC).  We found that fatty acid addition increased the phosphorylation of AMPK and ACC 
(Figure 2E-F), increased AMP levels ~30% (Figure 2G), and resulted in a small, but persistent 
increase in p-ACC following glucose addition (Figure 2F).  Interestingly, ZMP, an AMP analog 
known to activate AMPK, also increased after glucose addition with both BSA and fatty acid.  
However, ZMP remained elevated through the time course of insulin secretion in cells exposed 
to palmitate (Figure 2H), which may also contribute to the increased AMPK and ACC 
phosphorylation.   
Fatty acid caused an increase in de novo-synthesized glycerolipids.  To assess the effect 
of fatty acids on the formation of glycerolipids, we used LC-MS to quantify a series of lipid-
associated metabolites in INS-1 during GSIS using U-[13C]glucose to track de novo generation of 
glycerolipids containing palmitate.   In the absence of added palmitate, a small rise was seen in 
the M+3 isotopologues of LPA, palmitic acid (PA), diacylglycerol (DAG), triglycerides (TG), 
phosphatidylglycerol (PG) and phosphatidylinositol (PI) and monoacylglycerol (MAG) (Figures 
3A-H and Figure 1).  In contrast, total levels and M+3 isotopologues rose significantly in cells 
pre-incubated with palmitate (Figure 3A-H) with the rise in LPA preceding that of the other 
lipids, demonstrating a significant increase in the esterification of U-[13C]glycerol-3-phosphate 
(Go3P) (Figure 3A-H).  In INS-1 cells, the increase in DAG, previously suggested to play an 
important role in GSIS (6, 9), was primarily due to increases in M+3 species, suggesting that the 
bulk of DAG is generated de novo during GSIS in INS-1 cells.  We also observed increases in the 
labeling of phosphatidylcholine (PC), phosphatidyl ethanolamine (PE) and a parallel, rapid 
decrease in their precursor moieties, CDP-choline and CDP-ethanolamine, respectively (Figure 
3, I-L).  A mass shift of M+3 is detected for all these metabolites, except PG which shows M+6 





Figure ‎4-3.Palmitic acid effect on carnitines and glycerolipids metabolites.  Glycerolipids levels before and after stimulation 
with 16.6 mM U-[13C]glucose with and without preincubation with 500 µM palmitate for 30 min (time 0) and after 5 or 15 or 
60 min of glucose stimulation (A-I and K). CDP-choline (J) and CDP-eth (L) are measured after stimulation with 12C glucose. 
Error bars represent 1 S.E n= 3-4. 
 
Fatty acid exposure increases Sphingosine-1-Phosphate and N-acyl amide levels.   To 
further identify metabolites that could be implicated in fatty acid potentiation of GSIS, we used 
untargeted metabolomic profiling.  We found significant increases in sphingosine-1-phosphate 
and two acyl amides; palmitoyl taurine and palmitoyl glycine (Figure 4A-C) whose identities 
were confirmed by accurate-mass and retention time matching with standards.  Addition of 
taurine or glycine increased the levels of palmitoyl taurine and palmitoyl glycine, respectively, 
in the presence of palmitic acid (Figure 4, D and E).   Although significant increases in the 
palmitoylated species were observed, minimal effect on basal or GSIS was found (Figure 3F).   
Despite recent studies that suggest that acyl-taurine species added exogenously to β-cells 
enhanced GSIS, we did not detect changes in insulin secretion following addition of taurine (not 





Figure ‎4-4.undirected analysis for metabolites changing with fatty acid treatment. levels of palmitoyl glycine, palmitoyl 
taurine and sphingosine phosphate after incubation with fatty acid for 30 min followed by stimulation with 16.6 mM U13C 
glucose for 5,15 or 60 min (A-C). Levels of palmitoyl taurine and palmitoyl glycine after the addition of increasing dose of 
their precursor amino acids in the presence or absence of palmitate (D-E). Insulin levels after incubation of cells with BSA or 
palmitic acid in the presence or absence of glycine (F). Media was collected before addition of glucose (0 minute) or after 
stimulation with 16.6 mM glucose for 20 or 60 min. Error bars represent 1 S.E n= 3-4.  
Fatty acids increase glycolytic and TCA cycle carbon flux.   Following the addition of 
glucose, glycolytic and pentose phosphate intermediates rose as expected in both BSA and 
palmitate treated cells (Figure 1); however, palmitate blunted this rise.  By using U-[13C]glucose, 
we found that the levels of fructose-bis-phosphate fell (Figure 5A) due to a reduction in 13C-
labeled intermediates (Figure 5B).  Similar finding was observed other glycolytic intermediates 
(not shown) as well as in the pentose phosphate intermediates such as 6-phsophoglucanate 
and ribose+ribulose 5P (not chromatographically resolved) (Figure 5C-F).  Similar changes were 
seen in Go3P levels (Figure 5G and H).  Palmitate did not affect the glucose-induced rise in 
2PG+3PG 2-phospho + 3-phosphoglycerate (2PG+3PG), which are not chromatographically 





Figure ‎4-5.Palmitic acid effect on glycolysis, pentose phosphate metabolites and TCA cycle. Changes in levels of fructose 
bisphoshphate (A) phosphogluconate (C) ribose+ribulose-P (E), glycerol-3-phosphpate (G), 2PG+3PG (I), citrate (J), malate (K) 
and NADH (L) after stimulation with 16.6 mM 12C glucose in the presence or absence of 500 µM palmitate. Changes in total 
mass and 13C isotopologues after stimulation with 16.6 mM U13C glucose for fructose bisphosphate (B), phosphogluconate 
(D), ribose and ribulose-P (F) and glycerol-3-phosphate (H).  Error bars represent 1 S.E n= 3-4 except for control at 60 minute 
using 13C glucose, where n=2, and the values were confirmed with n= 4 in separate experiment. 
Because we found an increase in the flux of glucose into glycerolipids in the presence of 
palmitate, we hypothesized that the reduction in the glycolytic intermediates was due to their 
rapid consumption.  The conversion of dihydroxyacetone phosphate to Go3P utilizes NADH and 
we observed a significant reduction the NADH levels in palmitate treated cells following the 
addition of glucose (Figure 5L) as well as reduction in the NADH/NAD+ (Figure 1).  To confirm 
increased glucose flux to Go3P by fatty acid treatment, we performed a pulse chase experiment 
in which a 15 min pulse of U-[13C]glucose was chased for 2 min with unlabeled glucose in INS-1 
pretreated with BSA or palmitate.  The consumption of 13C-labeled Go3P as well as the 
generation of unlabeled Go3P was faster in the presence of fatty acid (Figure 6A), confirming a 
rapid increase of Go3P consumption following palmitate treatment.  Identical effects on 
metabolite flux were observed following preincubation of INS-1 cells with oleic acid 





Figure ‎4-6.palmitic acid effect on glycolytic flux, fatty acid oxidation and oxygen consumption.  For pulse-chase experiment, 
cells were stimulated with 16.7 mM U-13C glucose for 15 min (pulse) before the KRHB was replaced with the same media 
containing 16.7 mM 12C glucose for 2 min, after which the cells were quenched and the rate of consumption of labeled 
(Go3P) and the rate of formation of unlabeled (Go3P) in 2 min was plotted  (A). Statistics was done by comparing the slope of 
linear regression lines (ANCOVA) using GraphPad prism.  Oxygen consumption rate (OCR) and Extracellular acidification rate 
measured by sea horse system before and after the addition of 16.6 mM glucose (B and C). The percentage labeling of 
ultimate labeling of citrate, aspartate and malate after 1 hour treatment with U13C glucose (D). The % labeling of citrate 
after incubation of INS-1 cells with either BSA or U-[13C]palmitate or U-[13C]oleate for 30 min with no glucose (time zero) 
and after stimulation with 16.6 mM 12C glucose for 60 min (time 60) (E). Error bars represent 1 S.E with n= 3-4 for 
metabolites analysis and n= 10 for sea horse experiment. 
As a consequence of regeneration of NAD+ following palmitate treatment, an increase 
glucose flux into the TCA cycle would be expected.  Thus, we measured oxygen consumption in 
INS-1 cells pretreated with BSA or palmitate for 30 min.  As shown in Figure 6B, addition of 
palmitate produced a small increase in oxygen consumption rates (OCR) prior to the addition of 
glucose.  In contrast, preincubation with palmitate increased OCR by ~66% following the 
addition of glucose, demonstrating an increase in glucose oxidation.  Extracellular acidification 
rose following glucose addition, but was not affected by palmitate pretreatment (Figure 6C). 
  The rise in extra cellular acidification rate “ECAR”, a measure of lactate production, was 
small, consistent with the low levels of lactate dehydrogenase in these cells (24).  To further 
assess flux through the TCA cycle, cells were preincubated with BSA or palmitate and then for 




TCA intermediates revealed that fully labeled citrate (M+6), malate (M+4) and aspartate (M+4) 
were increased in the palmitate pretreated cells by approximately 35% (Figure 6D), supporting 
an increase of flux of glucose into the TCA cycle following palmitate treatment.    Finally, the 
minimal contribution of palmitate to oxygen consumption in INS-1 cells was confirmed by the 
low levels of 13C-carbon incorporation into citrate following exposure of cells to U-
[13C]palmitate or U-[13C]oleate in the presence or absence of glucose (Figure 6E).   
GPR40 receptor modulates FFA potentiation of GSIS and fatty acid esterification.  We 
next examined the role of the free fatty acid receptor FFAR1/GPR40 on metabolic flux in INS-1 
cells.  We first preincubated cells with the FFAR1/GPR40 antagonist, GW1100, in the presence 
or absence of 250 µM palmitate and measured insulin secretion and metabolite levels in 
response to the addition of 16.6 mM U-[13C]glucose for 30 min.  GSIS was decreased 
significantly by GW1100 inhibition of GPR40 receptor, both in the absence and presence of 
palmitate (Figure 7A) as previously described (7, 25).   Metabolite analysis showed that 
palmitate reduced the concentration of M+6 hexose phosphates as well as M+3 Go3P while 
GW1100-treated samples showed increased levels of M+6 hexoses (Figure 7B) as well as M+3 
Go3P isotopologues (Figure 7C) following preincubation with palmitate.   There was a parallel 
decrease in accumulation of M+3 isotopologues of LPA (Figure 7D) and various DAG species 
(Figure 7E and F) in antagonist treated cells following palmitate addition.  Conversely, the 
FFAR1/GPR40 agonist, Cay 10587, increased the M+3 isotopologues of DAG, but only in the 





Figure4- 7: GPR40 role in palmitic acid induced metabolic changes.  INS-1 cells were incubated with 250 µM palmitate or BSA 
in the presence or absence of 5 µM GPR40 antagonist (GW1100) for 30 min followed by stimulation with 16.6 mM U-
[13C]glucose for 60 min. Using these conditions the following are measured : insulin levels (A), changes in total mass and 13C 
isotopologues of glycerol-3-phosphate (B), Hexose phosphates (C), LPA (16:0), DAG(32:0) (E), DAG (34:1) (F) and its 
isoptologue ratio (J), CDP-ethanolamine (L).  INS-1 cells were incubated with 50 µM palmitate or BSA in the presence or 
absence of 10 µM Cay 10587 for 30 min followed by stimulation with 16.6 mM U-[13C] glucose for 60 min. Under these 
conditions, changes in total mass and 13C isotopologues of DAG(34:1) (G) and its isotopologues ratio (K) were measured.  
GPR40 was knocked down by siRNA and western blot is shown (H) for knocked down (KD) and non-transfected (control) or 
scrambled (non-targeting, NT). Under the knockdown conditions, INS-1 cells were incubated with 50 uM palmitate and 16.6 
mM U-[13C] glucose for 30 min and the ratio of DAG (34:1) isotopologues was compared between knockdown (KD) and 
scrambled (control) samples.  Error bars represent ± S.E n= 3-4. 
To further confirm that these effects were GPR40 mediated, we were able to partially 
knockdown GPR40 receptor using siRNA (Figure 7H) and assess the M+3/M+0 isotopologues of 
DAG (34:1).   GPR40 knocked down (KD) sample showed a significant decrease in the ratio of 
labeled/unlabeled DAG (34:1) (Figure 7I), similar to results seen in cells treated with the GPR40 
antagonist (Figure 7J) and opposite to the effect mediated by GPR40 agonist (Figure 7K). CDP-
ethanolamine increased in the presence of GPR40 antagonist (Figure 7L), which is in agreement 




Preincubation of INS-1 cells with GW1100 resulted in a ~2-fold increase in palmitoyl-
carnitine levels, suggesting an increase in flux of palmitate into the mitochondria (Figure 8A), an 
effect was also found in FFAR1/GPR40 knockdown cells (Figure 8B).   The FFAR1/GPR40 agonist 
had no effect on palmitoyl-carnitine levels when cells were incubated with low level (50 µM) 
palmitate (Figure 8C).  These results suggest that flux into glycerolipids is the primary 
determinant of fatty acid entry into mitochondria.  Neither antagonist (Figure 8D) nor agonist 
(Figure 8E) affected palmitoyl-CoA accumulation in the absence of glucose suggesting no effect 
of FFAR1/GPR40 receptors on fatty acid uptake or activation of the lipids by CoA synthase.   To 
assess the effect of FFAR1/GPR40 activation on lipolysis, we incubated INS-1cells with U-
[13C]palmitate with or without agonist for 20 min in the absence of glucose.  In the presence of 
agonist, there was an increase in the unlabeled DAG (34:1) and a decrease in the M+16/M+0 
labeling ratio (Figure 8F), consistent with previous reports of phospholipase C activation by the 
receptor (26).   
Finally, we assessed the effect of FFAR1/GPR40 receptor manipulation on palmitate-
stimulated glucose oxidation in INS-1 cells.  In the presence of agonist, there was a further 
increase in glucose oxidation in the presence of palmitate and Cay 10587 (Figure 8F).  
Conversely, the augmentation of glucose oxidation by palmitate was reduced by the antagonist 
(Figure 8G).  
 
Figure ‎4-8.Metabolic changes with GPR40 modulation. INS-1 cells were incubated with 250 µM palmitate +/- 5 µM GW1100 




time points. Levels of palmitoyl carnitine in the GPR40 knockdown experiment described in figure 6 (B). INS-1 cells were 
incubated with 50 µM palmitate +/- 10 µM Cay10587 GPR40 agonist  in absence of glucose for 30 min and the levels of 
palmitoyl-carnitine (C) and palmitoyl-CoA (E) were measured at different time points. INS-1 cells were incubated  with 50 µM 
U-[13C] palmitate in the  absence of glucose +/- agonist for 30 min and the ratio of labeled DAG(34:1)+16 to unlabeled 
DAG(34:1) was measured (F). Oxygen consumption rate in the presence or absence of agonist or antagonist (G and H). Error 
bars represent 1 S.E with n= 3 or 4 for metabolites analysis and n=6-7 for SeaHorse experiment 
 
Figure ‎4-9.Proposed pathways for fatty acid potentiation of glucose stimulated insulin secretion. Metabolic remodeling of 
glucose flux due to fatty acids and FFAR1/GPR40 activation in β-cells. 
 DISCUSSION 
The secretion of insulin is primarily regulated by the entry of glucose into the β-cell but 
is modulated by nervous system, hormonal, and nutritive inputs (27).  Fatty acids augment 
insulin release in vivo and in vitro and its effects have been shown to be mediated via 
intracellular metabolism and through surface receptors (8).  In this report we show that a 30 
minute incubation of INS-1 cells with palmitate prior to addition of glucose results in a doubling 
of insulin release as seen previously in intact islets (4).   Prior to glucose addition, palmitate 
exposure results in a ~7-fold increase in intracellular palmitoyl-CoA and a small increase in 
oxygen consumption, but little effect on basal insulin secretion and minimal changes in the 
majority of intracellular metabolites with the exception of a significant increase in the 
formation of palmitoyl-carnitine likely generated by the flux of fatty acid into the mitochondria.  
This suggests that despite a small increase in TCA cycle activity, there is minimal generation of 
factors necessary for insulin secretion.  Following addition of U-[13C] glucose, palmitoyl-CoA 
rapidly declines with the formation M+3 LPA and DAG isotopologues containing palmitate, 




glucose. This effect is not limited to saturated fatty acids as identical changes are seen following 
preincubation of INS-1 cells with oleic acid (Supplemental Figure 1).   
The esterification of fatty acids with Go3P has several effects that appear to contribute 
to their ability to augment insulin secretion.  We identified an increased glycolytic flux towards 
Go3P (Figure 6A and B), reduced NADH levels, and a decrease in NADH/NAD+ ratio following 
fatty acid addition (Figure 2 and 1).  As previously suggested (28), we show directly that fatty 
acid addition increases glycolytic (Figure 5A) and TCA cycle (Figure 6D) flux, and glucose 
oxidation (Figure 6B).  Each should result in the generation of additional stimulus-secretion 
coupling factors that have been suggested to arise from mitochondrial metabolism in β-cells 
(1). While fatty acids increased glucose oxidation, glucose addition reduced fatty acid entry and 
oxidation in mitochondria as indicated by the fall in C16 acyl-carnitine levels.  The reduction in 
fatty acid mitochondrial uptake has been attributed to increases in malonyl-CoA inhibition of 
CPT-1.  While malonyl-CoA levels rise with glucose, fatty acid addition results in a significant 
blunting of the rise in malonyl-CoA in INS-1 cells (Figure 2D).   The reason for the reduction is 
not clear, but decreased export of citrate/isocitrate from the mitochondria or an increase in 
consumption for de novo lipogenesis may play a role.  These results also suggest that the 
decrease in fatty acid oxidation following glucose addition may be primarily due to the 
redirection of acyl-CoA towards esterification rather than blocking influx to the mitochondria 
via CPT1 inhibition by malonyl-CoA. This is consistent with the results of Mulder et al. (29) who 
observed no effect on insulin secretion after reducing INS-1 malonyl-CoA levels by 
overexpression of a modified malonyl-CoA decarboxylase.    
The increase in de novo lipogenesis resulted in the generation of a variety of lipid 
intermediates that have been described as candidate signals for insulin secretion (8).  
Lipogenesis is part of the larger glycerolipid-free fatty acid cycle which is activated by glucose in 
β-cells and there is evidence that both the lipogenic and lipolytic arms of the cycle supply 
important signaling molecules (21).  In glucose-responsive INS-1 cells, we find that the majority 
of increases in whole cell lipid intermediates, including LPA, PA, DAG, PG, PI and MAG arise 
from the lipogenesis pathway as little increase in M+0 isotopologues are found even after 60 




activation of Munc13-1, a receptor known to amplify insulin exocytosis (30, 31) and activation 
of phospholipase D1 (PKD1), which modulates the reorganization of the cortical actin network, 
perhaps playing a role in the second phase of insulin secretion (6).  Recently, Prentki and 
colleagues have suggested that increases in MAG, generated by lipolysis of TAG in β-cells can be 
a better activator of Munc13-1 than DAG.      
In addition to previously identified lipid species, we found marked increases in cellular 
content of various acyl-amides.  These fatty acid derivatives have not been reported previously 
in β-cells and their effect is unknown.  Acyl-amides have been found in neuronal tissue and 
reportedly possess various functions (32, 33)  including modulation of calcium flux, nitric oxide 
generation (34), and TRP calcium channels (35). While, we were able to increase the 
intracellular concentration of those metabolites by increasing their amino acid precursor’s 
levels, this did not result in alterations in insulin secretion.  Interestingly, taurine has been 
suggested to restore β-cell insulin secretion following chronic fatty acid exposure. However this 
beneficial effect was attributed to its antioxidant ability (36). 
The activation of the FFAR1/GPR40 receptor mediates about 50% of the augmentation 
of insulin secretion by fatty acid (7). As indicated above, FFAR1/GPR40 has been proposed to 
increase β-cell calcium and activate phospholipase C generating diacylglycerols which may 
tether PKD1 to the plasma membrane increasing its activity (6), though the latter has not been 
directly demonstrated in β-cells.  We sought to determine whether acute modulation of 
FFAR1/GPR40 had an effect on the β-cell metabolome.  Disrupting FFAR1/GPR40 activity by use 
of antagonist and knockdown of the receptor resulted in attenuation of the augmentation of de 
novo DAG synthesis (Figure 7E, F, I, J).  In contrast, the FFAR1/GPR40 agonist, Cay10587 
increased flux of a low concentration of palmitate (50 µM) into DAG (Figure 7G and K).  In 
addition, GW1100 reduced oxygen consumption by INS-1 cells treated palmitate while agonist 
has an augmenting effect.  These results suggest that FFAR1/GPR40 enhances the effect of fatty 
acids to remodel intermediary metabolism.  This effect does not appear to be due to increased 
uptake or activation of fatty acid as disruption of FFAR1/GPR40 did not alter the levels of 




leading to de novo lipogenesis occurs following FFAR1/GPR40 activation, but modulation of 
GPAT activity may be a target, given the increased flux into the early steps of the lipogenic 
pathway.     
In summary, our data are consistent with the idea that in the fasting state, plasma fatty 
acids increase, increasing long chain acyl-CoA levels in β-cells.  There are both glucose and fatty 
acid oxidation, but no generation of coupling factors to increase insulin secretion (Figure 9A).  
As glucose levels rise after feeding, the presence of fatty acids increases esterification with 
glycerol-3-phosphate, resulting in an increased flux to glycolipids and the formation of lipid-
derived factors important in insulin secretion (Figure 9B).  The increased flux increases 
regeneration of NAD+, accelerating glycolysis and flux into the TCA cycle above that which 
would occur following exposure to glucose alone. Our data also suggests that in addition to the 
previously described activation of the PLC-PKD1 pathway (6), FFAR1/GPR40 activation also 
enhances flux through the glycerolipid pathway, augmenting the formation of coupling factors.  
This may be important as fatty acid entry into the β-cell likely falls as plasma fatty acids 
decrease following a meal due to insulin-mediated reduction in lipolysis in fat cells. Thus, 
activation of  the FFAR1/GPR40 receptor by fatty acids or receptor agonists (18) may ensure 
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Chapter 5. METABOLOMICS ANALYSIS REVEALS THAT AICAR 
AFFECTS GLYCEROLIPID, CERAMIDE AND NUCLEOTIDE SYNTHESIS 
PATHWAYS IN INS-1 CELLS 
 
INTRODUCTION  
 Beta cells in islets of Langerhans secrete insulin in response to high glucose levels in 
blood. Glucose stimulated insulin secretion (GSIS) is mainly dependent on glucose metabolism 
to generate signals that trigger or amplify insulin secretion (1).  Deterioration of beta cell 
function represents one of the factors responsible for development of metabolic syndrome and 
type 2 diabetes. 
An energy sensor that is located in all cells (including beta cells) is AMP-activated 
protein kinase (AMPK). AMPK switches between promoting catabolic and anabolic cellular 
processes to ensure energy balance depending upon nutrient availability (2). Increased AMP 
during starvation activates AMPK and subsequent activation of catabolic processes and 
inhibition of anabolic processes (3), on the other hand, high levels of glucose deplete AMP 
causing AMPK deactivation and subsequent activation of anabolic processes and inhibition of 
catabolic processes. 
Because of its effects on various metabolic pathways, AMPK is an interesting target for 
metabolic syndrome treatment.  Pharmacological agents like 5-Aminoimidazole-4-carboxamide 
ribonucleotide (AICAR) have been developed to activate AMPK. AICAR is a pro-drug that is 
uptaken by the cell and metabolized intracellularly into AICAR monophosphate (ZMP) which is 
an AMP analog. AICAR has been used to probe the effects of AMPK on several tissues in vitro, 
as well as in vivo (4). Intravenous administration of AICAR to diabetic patients decreased their 
hepatic glucose output and lowered their blood glucose and free fatty acids (5).  
Metabolic effects of AMPK activation varies from one tissue to another.  In adipocytes, 
AMPK activation inhibits hormone sensitive lipase, inhibiting lipolysis. In heart and 
macrophages, AMPK activation activates phosphofructokinase B2 and B3 respectively, 
activating glycolysis. In muscles and liver AMPK activation inhibits glycogen synthase 1 and 2, 




have been observed in multiple tissues, such as the inhibition of acetyl-CoA carboxylase 1 and 2 
(ACC1 and ACC2), inhibiting fatty acid synthesis and increasing fatty acid oxidation respectively. 
AMPK activation also inhibits 3-hydroxy-3 methylglutaryl CoA reductase (HMGR), inhibiting 
cholesterol synthesis (6, 7). 
AMPK activation effect on B-cell insulin secretion has been studied in islets or cell lines 
like (INS-1 cells) yielding conflicting results (8). AMPK over-expression in INS-1 cells significantly 
decreased glucose stimulated insulin secretion in the presence of fatty acid, this was attributed 
to the increased oxidation of fatty acid and the reduction in lipid signals involved in insulin 
secretion (9). The reduction in lipid messengers was the same reason AMPK activation by AICAR 
was able to rescue INS-1 beta cells from saturated acid induced toxicity (10). On the other hand, 
AMP activation by AICAR was shown to potentiate insulin secretion from rat islets and INS-1 cell 
lines at low glucose, with no significant effect at higher glucose levels (11).   
Although AICAR’s primary mode of action is thought to be as an AMP mimetic that 
causes AMPK activation, some effects of AICAR have been shown to be independent of AMPK 
activation. AICAR inhibited choline kinase and phosphatidyl choline synthesis in liver cells 
independent of AMPK (12). AICAR has also been shown to induce apoptosis in chronic 
lymophcytic leukemia cells independent of AMPK leading to clinical studies on this treatment 
(13).  AMPK independent effects induced by AICAR were protective in animal models of human 
malignant hyperthermia from sudden death. This useful effect was suggested as a possible 
prophylactic treatment for the human disease (14). 
In light of the widespread use of AICAR as an activator of AMPK for research purposes 
and the growing interest in use of AICAR as a treatment for certain human diseases, improved 
understanding of the molecular basis of its action is essential.  As AICAR directly affects many 
aspects of cellular metabolism, metabolomics may be expected to provide valuable insight into 
the effects of AICAR. Global intracellular metabolite changes associated with AICAR treatment 
have been studied in human umbilical vein endothelial cells using NMR techniques (15). In 
hepatocytes, a few alterations in metabolite levels were reported, including a decrease in ATP 




metabolite changes were studied recently in T-cells using LC-MS and showed an increase in 
secreted purine and pyrimidine intermediates (17). 
We have recently shown that ZMP is an endogenous metabolite that increases after 
glucose stimulation in INS-1 cells which could be a negative regulator for insulin secretion, 
however we did not investigate its role in detail (1). So a follow up experiment was performed 
to study the acute effect of ZMP on beta cell metabolism and insulin secretion using INS-1 
832/13 cells. We applied metabolomics isotopic nutrients to investigate various pathways. We 
were able to identify different AMPK dependent and independent pathways as well as 
identifying metabolomics markers or fingerprint for AMPK activation in beta cell. 
MATERIAL AND METHODS  
Materials.  INS-1 cells (18) were kindly provided by Dr. Christopher Newgard (Sarah W. 
Stedman Nutrition and Metabolism Center, Duke University, Durham, NC).  All chemicals were 
purchased form Sigma-Aldrich (St. Louis, MO) unless otherwise noted. RPMI media, fetal bovine 
serum, 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), and penicillin-streptomycin 
were purchased from Invitrogen Corp, (Carlsbad, CA). Stable isotope labeled U-13C glucose and 
ethanolamine were purchased from Sigma.     
Cell culture.INS-1 832/13 cells were cultured in RPMI supplemented with 2 mM 
glutamine, 1 mM sodium pyruvate, 10% FBS, 10 mM HEPES, 100 U/mL penicillin, 100 µg/mL 
streptomycin, 250 ng/mL amphotericin B, and 50 µM β-mercaptoethanol.  Cells were plated at 
a density of ~14 x 103 cells/cm2 and grown in 6 cm culture dishes at 37 °C and 5% CO2 in a 
humidified atmosphere to ~70% confluence. Krebs-Ringer-HEPES buffer (KRHB) was prepared 
containing  20 mM HEPES, 118 mM NaCl, 5.4 mM KCl, 2.4 mM CaCl2, 1.2 mM MgSO4, and 1.2 
mM KH2PO4 and was adjusted to pH 7.4 with NaOH.  
Experimentation. On the day experiments were performed, the cell culture medium 
was changed to KRHB containing 2 mM glucose +/- 250 uM AICAR for 60 min prior to addition 
of 10 mM 12C or 13C glucose from 1 M stock solution. Cell metabolism was quenched at 
different time points as described in each experiment. For the dose response curve of AICAR, 
cells were incubated with 10 mM glucose and serial concentration of AICAR (0, 25, 125,250 and 




CDP-ethanolamine, cells were incubated in RPMI with 3 mM glucose or 10 mM glucose for 6 
hours before quenching. 
Glycerolipids pathway monitoring. For DAG and ceramide analysis, the INS-1 (832/13) 
clonal cell line was incubated with 2 mM glucose, 250 uM AICAR and 50 uM palmitic acid for 1 
hour before stimulation with 13C glucose for 30 minutes. In the case of CDP-ethanolamine 
labeling, labeled ethanolamine was also added for the 1 hour pre-incubation period.  
Insulin measurement and western blot. For insulin, aliquots of supernatant was diluted 
with 1% BSA and stored at +4 °C before being assayed using Rat/Mouse insulin ELISA Kit 
(Millipore, Billerica, MA).  For western blot, cells were washed with cold PBS before the 
addition of lysis buffer (RIPA buffer supplied with complete protease inhibitor cocktail and 
phosphatase inhibitor cocktail (Roche diagnostics)). Anti-phospho-Acc, anti-phospho-HMGR 
antibodies were obtained from Cell signaling.) Blots were developed with ECL (Pierce) according 
to manufacturer's instructions. 
Metabolite Measurement. Cell plates were rinsed, metabolism quenched, and 
metabolites extracted using the procedure described previously (1). Briefly, cell plates were 
rapidly rinsed with water and quenched with liquid nitrogen. Metabolites were extracted with 
8:1:1 methanol: chloroform: water and assayed by high performance liquid chromatography 
with time-of-flight mass spectrometry (HPLC-TOF-MS). Chromatographic separations were 
performed with an Agilent Technologies (Santa Clara, CA) 1200 HPLC system equipped with a 
Phenomenex (Torrance, CA) Luna NH2 2.0 × 150 mm, 3 μm HPLC column and a 2.0 × 4 mm 
guard column using the following conditions: mobile phase A was 100% acetonitrile (ACN); 
mobile phase B was 100% 5 mm ammonium acetate pH 9.9 with ammonium hydroxide. Lipids 
were separated on a C18 Capcell column (2 mm bore by 150 mm long packed with 3 μm 
particles). Mobile phases and gradient are similar to that described in (19) . Detection was 
performed on an Agilent Technologies LC/MSD TOF using dual electrospray ionization (ESI) 
source in negative-ion mode for polar metabolites and both negative and positive mode for 
lipids.  
Data analysis and statistics. Directed analysis was performed to measure Metabolites 




identified using standards, accurate mass, and isotope ratios to confirm peak assignments as 
described in (1) 
Undirected analysis was performed using XCMS online (20). Hits with significant 
increase was manually checked for correct assignment.  These metabolites were identified by 
searching both Human Metabolome Database and Metlin to match mass and comparing to 
standards. For relative quantification of identified metabolites, peak areas were used as 
described before. 
For all studies, peak areas were measured from extracted ion chromatograms of [M-
H]− metabolite ions with ± 70 ppm detection windows centered on the theoretical mass. [M-
2H]2− ions were used for malonyl-CoA (mCoA) and other CoAs to improve sensitivity. Statics 
was performed using unpaired student-t test comparing different time points +/- AICAR, with 
significance value <0.05 
RESULTS 
AICAR effect on insulin secretion and metabolome of beta cell 
The effect of 0 uM to 1250 uM AICAR treatment for 60 min on ZMP formation was 
tested. As shown in supplemental figure 1, ZMP increased linearly with AICAR concentration up 
to 250 uM where it began to level off. For all subsequent studies we used 250 uM which was 
within the linear range and generated a ZMP concentration that was ~150 times greater than 
the highest endogenous levels. This AICAR concentration is an intermediate value relative to 
previous studies, which used doses ranging from 100-1000 uM (12, 16). 
The effect of AICAR on insulin secretion was evaluated by incubating INS-1/832 (13) cells 
in KRB with 2 mM glucose for 60 minutes in the presence or absence of 250 uM AICAR. This 
pretreatment was intended to allow the uptake of AICAR and its conversion into the active form 
before stimulation with 10 mM glucose. Insulin secretion was measured after the incubation 
period at low glucose (time zero) and after 60 minutes of high glucose. At low glucose, AICAR 
substantially increased insulin secretion; however, after stimulation with elevated glucose the 
total amount of insulin secreted was unaffected by AICAR. Because of the difference in basal 
secretion, the stimulation index was significantly reduced in the presence of AICAR (Figure 1). 




figure 2. These results are also consistent with our previous study that showed that if 10 mM 
glucose and 25 uM AICAR were applied simultaneously to a cell, insulin secretion was slightly 
reduced at 45-60 min.  
To determine the effect of AICAR on the INS-1 cell metabolome, metabolism was 
quenched and metabolites extracted for LC-MS analysis at different times before and after 
glucose treatment. LC-MS analysis of cell extracts allowed monitoring of 66 identified 
metabolites. The relative change in metabolite concentration between AICAR treated sample 
and control at different times during glucose treatment is summarized in figure 1. The results 
show that AICAR affected many metabolites involved in a variety of pathways. Some of these 
pathways are known to be associated with AMPK activation, while others are not.  Results from 






Figure ‎5-1.insulin and metabolites changes with AICAR incubation (a) insulin level after AICAR incubation and after glucose 
stimulation for 60 minutes.(b) formation of ZMP with AICAR incubation (C) phosphoACC after AICAR incubation and after 











































































































































































































glucose treatment for 10 and 20 minutes. (D) Heat map showing fold change of metabolites with AICAR treatment. 
Significantly different values are highlighted with asterisk. Student t-test was performed on each time points comparing the 
control and AICAR treated samples.  
 
AICAR decreased malonyl CoA and long chain CoA levels. 
Incubation of cells with AICAR increased ZMP levels after the incubation period, that 
decreased after glucose addition (figure 1b) (p < 0.05).In the absence of AICAR, glucose 
increased ZMP ~ 5 fold, as we have shown previously (1), but still far below that evoked by 
AICAR alone (Figure 1B, C).  
ZMP is known to activate AMPK which in turn phosphorylates and deactivates ACC. We 
confirmed this effect by determining ACC1 phosphorylation using western blot. Phospho-ACC 
increased with AICAR treatment, but then decreased with glucose stimulation (figure 1). These 
results indirectly show that the AICAR treatments used can modulate AMPK activity and that 
elevated glucose opposes the effect, mirroring the changes in intracellular ZMP. A key 
metabolic marker of this effect is malonyl CoA, the product of ACC. Malonyl CoA increases with 
glucose treatment, but AICAR lowered the concentration throughout the glucose treatment 
(Figure 2A). The substrate of ACC, acetyl CoA, was unaffected by AICAR suggesting other 
regulation of its steady state concentration. This was expected because Acetyl CoA was 
previously shown to be stable (1).   
The ratio of malonyl CoA to acetyl CoA more clearly shows the apparent effect of ACC 
phosphorylation evoked by AICAR (Figure 2C). Malonyl CoA inhibits CPT-1 and fatty acid 
oxidation with a consequence of increasing availability of long chain CoA in cytosol. As 
expected, AICAR reduced long chain CoAs at low glucose (time 0 in Figure 2B). Interestingly, 
glucose treatment without AICAR also decreases long chain CoAs. We have shown that this is 
due to consumption by reaction with glycerol phosphate, which dramatically increases with 
glucose treatment, to produce glycerolipids. While AICAR reduces long chain CoAs at low 
glucose, its effect is not additive with glucose so that at high glucose the effect of AICAR is nil on 





Figure ‎5-2.metabolites affected by ACC deactivation. (a) Malonyl-CoA. (b) palmitoyl CoA. (c) ratio of malonyl CoA/acetyl 
CoA.(d) AMPK effect on malonyl-CoA formation. Cells were incubated with/without AICAR for 1 hour, followed by 
stimulation with 12C glucose for different time points. 
AICAR increased HMG-CoA and decreased farnesyl pyrophosphate 
AMPK also phosphorylates and deactivates HMG-CoA reductase. We found that 
phospho-HMG-CoA was increased by AICAR treatment (Figure 3D), again indirectly showing 
that the AICAR concentrations used activate AMPK. The substrate of HMG-coA reductase, 
HMG-CoA, decreases substantially with glucose treatment. AICAR did not affect the initial 
concentration but did blunt the decrease evoked by glucose (Figure 3A). Farnesyl 
pyrophosphate, a downstream product of HMG-CoA, was also not strongly affected at low 
glucose, but its increase induced by glucose was blunted by AICAR (Figure 3B). The combined 
effects, plotted as the ratio of FPP/HMG-CoA suggest that AICAR deactivation of HMG-CoA 
reductase lowers flux through this pathway and reduces net concentration of downstream 
products even with elevated glucose (Figure 3C). This would lie in agreement with AICAR 
reduction of cholesterol accumulation in myotubes(21) and macrophages(22).  
 
Figure ‎5-3. Metabolites affected by HMGR deactivation. (a) HMG-CoA, (b) Farnesyl pyrophosphate (c) ratio of Farnesyl 
pyrophophate/ HMG-CoA. Cells were incubated with/without AICAR for 1 hour, followed by stimulation with 12C glucose for 
different time points.(d) Phospho-HMGR levels after cells incubation in the presence or absence of AICAR for 1 hour. (e) 
AMPK effect on mevalonate pathway.  
AICAR did not affect glycolysis or TCA metabolites 
Glucose stimulation is known to increase flux into glycolytic pathway and TCA cycle that 




pathways are affected by AICAR, key metabolites involved in glycolysis and the TCA cycle were 
analyzed and did not show significant differences (figure 1). 13C labeling of fructose 
bisphosphate and citrate after exposure of cells to U13C glucose for 30 minutes was analyzed as 
representative measure of flux in glycolysis and TCA cycle, respectively, but no significant 
effects of AICAR were detected (figure 4).This was consistent with the lack of effect on the ratio 
of ATP/ADP at early time points (figure 1). However, AICAR slightly increased ATP/ADP ratio 
after 25 minutes of glucose treatment, which was mainly because of the decrease in ADP 
concentration (described below). 
  
 
Figure ‎5-4.Effect of AICAR on TCA cycle and glycolysis: levels of the different isopotomers (a) Fructose bisphosphate (b) 
Citrate  
 
AICAR decreased GAR and PRPP with slight change in pentose phosphate shunt metabolites 
and decreased glucose flux in the purine and pyrimidine pathway. 
Our metabolomic analysis also showed significantly lower levels of glycinamide 
ribonucleotide (GAR) and phosphoribosyl pyrophosphate (PRPP) after glucose treatment (figure 
1). PRPP is a metabolite that links the pentose phosphate pathway with the purine and 
pyrimidine synthesis pathway. Glycinamide ribonucleotide (GAR) is one of the metabolites in 
the early steps of the purine synthesis pathway (figure 5G). Both PRPP and GAR increase 
significantly in control cells after glucose stimulation (1); however, AICAR incubation 
significantly blunted this increase (figure 5A, B) suggesting decreased activity in this pathway. In 
accordance with this finding, the substrate pentose phosphates increased slightly with AICAR 




To further understand the effect of AICAR on GAR and PRPP concentration, we used 
uniformly 13C labeled glucose to monitor the flux of glucose in the purine and pyrimidine 
pathway. Using uniformly 13C labeled glucose, newly synthesized ATP and UTP could be 
measured by LC-MS, by observing the 5 Dalton mass increases caused by addition of a 13C5-
labeled ribose sugar to adenine or uridine. The levels of 5 labeled ATP or UTP decreased 
significantly in the presence of AICAR (Figure 5E). The labeling of pentose phosphate 




Figure ‎5-5.Effect of AICAR on pentose phosphate and purine pathway metabolites:  (a) GAR (b) PRPP (C) pentose phosphates 
(d) +5 labeled pentose phosphates. (e) Unlabeled ATP and UTP levels (f) +5 labeled ATP and UTP. Cells were incubated 
with/out AICAR for 1 hour, followed by stimulation with 12C glucose for different time point (a-c) or using 13C glucose for 30 
minutes (d-f). The percentage of maximum was calculated based on the maximum of each species.(e) the purine and 





AICAR affected Kennedy pathway of phosphatidyl ethanolamine synthesis and decreased 
flux of glucose in glycerolipids pathway and decreased ceramides 
Undirected metabolomic analysis of polar metabolites revealed an increase in CDP-
ethanolamine with AICAR incubation (figure 6A and supplemental figure 2). According to the 
Kyoto Encyclopedia of Genes and Genomes (KEGG) (23, 24), CDP-ethanolamine is used only in 
de novo phospholipid synthesis (Kennedy pathway) (Figure 7E). This increase is in agreement 
with previous data showing an increase of CDP-ethanolamine in hepatocytes with AICAR 
treatment (16). The AICAR induced increase in CDP-ethanolamine was also induced by low 
glucose (figure 6 B), which suggests that the increase in CDP-Et is AMPK dependent. To confirm 
the peak assignment (since no authentic standard is available for this metabolite) and to 
understand the reason for this increase of CDP-ethanolamine, we incubated cells with 2-13C 
labeled ethanolamine in the presence or absence of AICAR. Labeled CDP-ethanolamine was 
formed and co-eluted with the unlabeled form, confirming correct peak assignment (figure 6 D, 
E, G). Both the labeled and the unlabeled CDP-ethanolamine increased with AICAR treatment 
(figure 6C) suggesting inhibition of consumption of CDP-enthanolamine rather than an increase 





Figure ‎5-6.Effect of AICAR on metabolites in the Kennedy pathway for PE: (a) CDP-ethanolamine after incubation 
with/without AICAR for 1 hour followed by stimulation with glucose for different time points (b) CDP-ethanolamine levels 
after starvation for 6 hours at low glucose (c) levels of labeled and unlabeled CDP-ethanolamine-after incubation with +2 
ethanolamine for 1 hour and stimulation with glucose for 30 minutes. (D, E, G) EIC and mass spectrum of labeled and 
unlabeled CDP-ethanolamine-after incubation with +2 ethanolamine for 1 hour before glucose treatment for 30 minutes (f) 
Levels of CDP-ethanolamine after phospholipase inhibition. Cells were incubated at 2 mM glucose for 60 minutes +/- AICAR 
+/-phospholipase C (PLC) inhibitor (U-73122) 20 uM  or +/-  phospholipase D inhibitor Cay10593 (60 uM).  
In the Kennedy pathway, CDP-enthanolamine is consumed by condensation with 
diacylglycerol (DAG) to form Phosphatidyl ethanolamine (PE). To confirm that flux of DAG into 
PE formation is reduced, we incubated cells with 50 uM palmitic acid for 1 hour before the 
addition of U13C glucose to allow lipogenesis and formation of 13C3-labeled glycerolipids (figure 
7). By observing the labeling ratio (+3 labeled/unlabeled glycerolipids) it is evident that AICAR 
induced a consistent decrease of glucose flux into the glycerolipids pathway. This was also 
coupled with an accumulation of Go3P as shown in supplementary figure 3.  The decrease in 
glucose flux in the glycerolipids pathway was true in DAG and PC but surprisingly not in PE. This 




enzyme in the Kennedy pathway did not change PE levels. This was attributed to a balance 
between formation of PE and phospholipase activity that results in maintenance of PE pools at 
steady-state levels regardless of alterations in flux. 
 To confirm the existence of this equilibrium between lipolysis and lipogenesis we 
attempted to inhibit phospholipase C or D using previously described inhibitors (U-73122 and 
Cay10593 respectively(26, 27)).  We observed a significant increase in CDP-ethanolamine that 
was augmented by the addition of AICAR (figure 6F). This accumulation of CDP-ethanolamine 
would imply less flux into PE in response to phospholipase inhibition. This flux was further 
inhibited by AICAR, which caused even more accumulation of CDP-ethanolamine. This would 
support the hypothesis of continuous PE formation and breakdown by phospholipases, keeping 
PE at steady-state levels. Based on these data, we conjecture that decreased formation of PE 
from DAG is partially due to reduced availability of the substrate (DAG), but also because of the 
inhibition of EPT enzyme. This suggestion is supported by the fact that CDP-ethanolamine 
accumulated mainly under low glucose conditions where there is low glucose flux and low 
lipogenic activity.  
To detect other possible effects of AICAR on lipids, untargeted metabolomics analysis 
was applied to the previous experiment using 50 uM palmitic acid and U-13C glucose. The most 
prominent identified changes were ceramides, which decreased significantly with AICAR 








Figure ‎5-7.effect of AICAR on Ceramides and glycerolipids synthesis pathway:  (a-c) ratio of +3 labeled DAG,PC or PE( 34:1) (d) 
Ceramides levels. INS-1 cells incubated with 50 uM palmitic acid with or without AICAR 250 uM for 1 hour before stimulation 
with U-13C glucose for different time points (e) Kennedy pathway for phospholipid synthesis: ECT-ethanolamine phosphate 
cytidylyltransferase, EPT-ethanolamine phosphotransferase, GPAT-glycerol-3-phosphate O-acyltransferase, PSS-1 and PSS-2: 
phosphatidylserine synthase 1 and 2 
DISCUSSION 
We used an LC-MS based metabolomics method to probe the metabolic effect of AICAR 
on the β-cell line INS-1. The effects of AICAR treatment on β-cell lines were observed in a 
diverse range of metabolic pathways and appear to be mediated by both AMPK-dependent and 
independent processes.  These pathways appear to be relevant to the β-cell secretory function 
as well as the cancerous nature of the cell line. These pathways might represent novel targets 
for future development of treatments for diabetes and cancer.  
Effect of AICAR on GSIS related pathways. 
The metabolomics method allows us to evaluate the effect of AICAR on several key 




5 min of glucose stimulation as expected to trigger first phase insulin secretion (1). AICAR did 
not affect ATP/ADP ratio at early time points, but evoked a slight increase after 25 minutes. This 
increase in ATP/ADP ratio is because of a decrease in ADP concentration presumably because of 
the ZMP induced inhibition of purine synthesis (figure 1 and 5).  
AICAR modulated the long chain coA pathway, presumably through activation of AMPK 
and its effects on ACC. AICAR lowered the levels of long-chain CoAs which is known to have 
several roles in GSIS. Long-chain CoAs can potentiate opening Katp so that decreases in long-
chain CoA’s may be stimulatory to GSIS (1). Consistent with this idea, we and others have found 
that glucose lowers the long chain CoA concentration (28). AICAR lowered the long-chain CoA 
concentration at low glucose, but did not significantly lower it further with glucose stimulation. 
These results are consistent with elevated basal insulin secretion that does not increase 
substantially with glucose. 
The succinate pathway proposed to enhance GSIS involves the formation of HMG-CoA 
through HMG-CoA reductase (HMGR) (29). The inhibition of HMGR by statin drugs has shown to 
inhibit glucose stimulated insulin secretion (29). Supporting the potential importance of this 
pathway, we have previously shown that glucose increases flux through HmgCoA yielding net a 
decrease in HmgCoA and an increase in FPP, a downstream metabolite that is involved in 
prenylation of proteins (1). Such modifications may promote exocytosis. AICAR blunted the 
effects of glucose resulting in higher HmgCoA and lower FPP. Such results are consistent with 
inactivation of HmgCoa reductase  by AICAR through AMPK and could explain some of the 
inhibitory effects on GSIS.  
Glycerolipid synthesis pathway is believed to be involved in promoting and sustaining 
GSIS (30). Products like DAG may be proximal metabolites in exocytosis while pathways 
supporting production of these compounds are critical for providing a supply at the proper time 
for GSIS. AICAR evoked a number complex changes, including a decrease in DAG, that may be 
linked to its net inhibitory effect on GSIS. The decrease in glucose flux in the glycerolipids cycle, 
would suggest that this decrease in DAG is probably due to reduced glycerol-3-phosphate and 
LC-CoA esterification by GPAT This is in agreement with the idea that GPAT enzyme could be a 




screening (Figure 1), it accumulated in the presence of 50 uM palmitic acid (supplementary 
figure 3) because of increased flux in the glycerolipids pathway. Similar accumulation of Go3P 
was seen before in myoloma cell (32). Although we suggest GPAT inhibition by AICAR we 
cannot exclude the possibility that the reduced esterification could be due to decreased LC-CoA 
levels. 
The reoxidation of NADH to NAD+ is critical to maintaining glycolytic flux into the 
mitochondria and for GSIS (33). The formation of Go3P from dihydroxyacetone phosphate 
(DHAP) by cytosolic glycerol-3-phosphate dehydrogenase utilizes NADH to regenerate NAD+, 
allowing continuing flux through glycolysis (1). The ratio of NADH/NAD+ slightly increased with 
AICAR, indicative of less esterification of Go3P with LC-CoA which might also explain some of 
the inhibitory effect on GSIS. 
ZMP effect on survival pathways 
The results point to several ways that AICAR may mediate survival or growth of cells. 
AICAR decreased the denovo synthesis of purine and pyrimidine metabolites by decreasing 
glucose flux through these pathways. Slight accumulation of pentose phosphate metabolites 
was seen, which would suggest that AICAR caused an inhibition in enzymes that links the 
pentose phosphate pathway with the purine and pyrimidine pathway. These enzymes could be 
PRPP synthase, the enzyme responsible of formation of PRPP and/or PRPP amido transferase 
which catalyzes the conversion of PRPP and glutamine to ribosyl amine-5 phosphate which 
forms GAR (figure 5E). Interestingly, both enzymes are known to be inhibited by metabolites in 
the purine synthesis pathway, like AMP, ADP, GMP and GDP (34, 35). This inhibition could be 
mediated by ZMP, which is an AMP analog based on being a purine derivative and probably not 
through AMPK. These observations and conclusions would support a plausible explanation for 
the decrease in ATP seen before in hepatocytes (the main site for purine synthesis) after AICAR 
treatments (12).This effect might also put AICAR in the category of an anti-metabolite therapy 
for cancer treatment. Interestingly it was shown recently that AICAR induced apoptosis in 
cancer cells independent of AMPK activation (13). Indeed, it has recently been shown that 
AICAR was able to induce apoptosis in multiple myoloma cells independent of AMPK (32). The 




mainly UMP synthase, which would agree with another published data (17). Although the 
metabolites measurements was done at 8 hours compared to our 60 minutes, but they 
observed a decrease in PRPP as we have shown. 
 Another metabolic change that is highly relevant to β- cells is the significant decrease in 
ceramides seen with AICAR incubation. Ceramides are suggested to be a lipid second 
messenger responsible for β- cell death after its exposure to saturated fatty acid (36).  This 
decrease in ceramides agrees with other work showing that showed that AMPK activation by 
AICAR inhibited serine palmitoyl transferase II (SPT II) and lowered palmitate induced ceramide 
formation in skeletal muscle (37). Serine levels decreased in a dose dependent manner after 
the addition of a range of concentrations of AICAR as shown in supplemental figure 2. This 
inhibition of SPT II could then be a consequence of less substrates availability, mainly palmitoyl 
CoA and serine. The two findings of decreased flux in the glycerolipids synthesis pathway and 
decreased ceramides synthesis in β- cells could help explain the finding that AICAR decreased 
palmitic acid induced apoptosis in INS-1 cells (10). 
Metabolic markers for enzyme activities 
An LC-MS run for a metabolomics study could provide plenty of information for enzyme 
activities and act as confirmation for immunoassay studies. It might also act as the sole marker 
for enzyme activity if no antibodies are available. Malonlyl CoA could be a useful marker for 
ACC activity as we have shown. Even better ratio would be the ratio of malonyl-CoA to acetyl-
CoA that would benefit from the stable levels of acetyl-CoA and help normalizing metabolites 
for any variation in cell mass, extraction or instrumental sensitivity, a major concern in 
metabolomics. HMG-CoA accumulation and the reduction of FPP levels would also provide a 
“finger print” for HMGR inhibition, and the ratio of HMG-CoA to FPP would also help 
normalizing the variation and provide a sensitive marker for HMGR activity. 
CDP-ethanolamine metabolite is an interesting metabolite marker that is readily 
detectable and involved only in the glycerolipids pathway. The current study showed that this 





Metabolomic profiling revealed alterations in numerous biochemical pathways, which 
provide insight into the response of β- cells to a simulated “starvation” condition.  Stable 
isotope labeled glucose provided more detailed information regarding metabolic flux in 
pathways of interest. We highlighted metabolomic markers that act as a metabolic fingerprint 
of AMPK activation and confirm immunoassay measurements. U- 13C-glucose treatment 
revealed a decrease in glucose flux in the purine and pyrimidine pathway, suggesting an 
inhibition in PRPP synthase and/or PRPP amidotransferase enzyme by ZMP. Using labeled 
ethanolamine, we showed that AICAR may inhibit EPT via an AMPK dependent process. We also 
showed the fine equilibrium in lipogenesis and lipolysis that can be probed by CDP-
ethanolamine levels. Using U- 13C glucose and the ratio of labeled/unlabeled DAG we showed a 
decrease in glucose flux in the glycerolipid synthesis pathway suggesting an inhibition of GPAT 
enzyme. Undirected metabolomics showed a decrease in ceramides that might help to explain 
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Figure S2: dose response curve: levels of ZMP, CDP-ethanolamine and serine after increasing dose of AICAR. 
  
Figure S3:  levels of G3P after incubation of INS-1 cells with 50 uM Palmitic acid, 2 mM glucose and ethanolamine +/- 250 uM 
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Chapter 6. SUMMARY AND FUTURE PLANS 
SUMMARY  
We developed and optimized a method for non polar metabolite extraction and analysis 
using LC-MS.  Different stationary phases were investigated including HILIC and reverse phase. 
As expected, HILIC separated lipids into classes based on its head group, while reverse phase 
separated lipids based on their chain length. HILIC provided superior separation for some low 
abundant lipid classes such as phosphatidyl serine, while reverse phase separation provided 
better separation for the rest of lipid classes. Different reverse phase stationary phases with 
various chain lengths were evaluated, such as C8, C18 and C30. The compromise chain length of 
C18 was more suitable for global lipid separation than the C8 or C30. We evaluated the impact 
of temperature and mobile phase pH on lipids separation and detection. Different extraction 
solvents were screened to evaluate its efficiency for lipid extraction. The final method for non 
polar metabolites analysis was combined with a HILIC based method for polar metabolites 
analysis, providing an analytical platform for global metabolites analysis. Using different 
metabolic tracers, this analytical platform enabled flux monitoring in different metabolic 
pathways such as glycerolipids pathway and central carbon metabolism.  
We were able to successfully apply this developed analytical platform for several 
biological questions, with main focus on beta cell and its ability to secrete insulin in response to 
different stimuli. The first question was to understand metabolic changes during glucose 
stimulated insulin secretion. Using U13C glucose we were able to probe metabolic changes that 
took place in the first 10 minutes of insulin secretion. We showed that U-13C glucose induced an 
increase in several metabolites, such as those involved in glycolysis and TCA cycle. This increase 
in metabolite levels was mainly derived from newly added glucose. We showed that malate was 
exception for this observation, where the glucose induced increase was mainly derived from 
aspartate, presumably through the aspartate malate shuttle. By blocking the aspartate-malate 
shuttle; we reduced this glucose induced increase in malate and confirmed the importance of 
this shuttle in insulin secretion. Using U13C glucose, we monitored glucose flux in the 




stimulation.  Those novel findings are important to understand how glucose regulate insulin 
secretion and what are metabolic pathways involved in glucose stimulated insulin secretion. 
The second biological question was to understand why fatty acids can potentiate 
glucose stimulated insulin secretion. This is representative of the hyperinsulinemia condition, 
which precedes the development of type 2 diabetes. We showed that fatty acids increase 
glucose oxidation, while being minimally oxidized by beta cell. Most fatty acids were esterified 
with glycerol-3-phosphate, derived from glucose and forming several glycerolipids signals that 
are known to facilitate insulin exocytosis. The increased glucose flux into glycerolipids pathway 
and the increased glucose oxidation are novel findings that were not reported before that 
would help understanding this potentiation mechanism. We also applied undirected 
metabolomics analysis and we found novel lipid signals that increased with fatty acid treatment 
such as palmitoyl glycine and palmitoyl taurine.  The role of those acylamides is yet to be 
investigated. 
Although the potentiation of fatty acid for insulin secretion appeared to be mainly 
mediated by the metabolism of fatty acid, the effect of free fatty acid receptor was reported to 
contribute to this potentiation mechanism. We were able to block and knockdown GPR40 
receptor and study metabolic changes associated with the inhibition of this receptor. 
Interestingly metabolic changes induced by fatty acid were partially reversed after GPR40 
inhibition. Inhibition of GPR40 led to the divergence of fatty acid away from esterification and 
towards oxidation in the mitochondria. These data suggest for the first time a role of GPR40 in 
glucose and fatty acid metabolism. This data would also justify the current development of 
GPR40 agonist drugs towards the treatment of type 2 diabetes.  
We further investigated the effect of AMPK activation on beta cells and GSIS. We used a 
pharmacological agent (AICAR) which is known to activate AMPK. AMPK is metabolic master 
switch that activated by AMP and is known to regulate many metabolic pathways. AICAR was 
developed as an AMP analog, capable of activating AMPK and was suggested to be used in the 
treatment of type 2 diabetes. We showed that AICAR reduced insulin secretion stimulatory 




known to contribute to the GSIS response. These attenuated pathways include the glycerolipids 
and mevalonate synthesis pathway. We showed also the danger of using AICAR as a purine 
analog for AMPK activation, because this would lead to the inhibition of the purine and 
pyrimidine synthesis pathway, which might lead to cell apoptosis on the long term. We also 
showed that AICAR decreased ceramides levels, which are known signals for beta cell apoptosis.  
Those novel findings would further augment importance of glycerolipids and mevalonate 




  Acute exposure of beta cells to fatty acid will potentiate GSIS as described in chapter 4 
while the chronic exposure to fatty acids and glucose will lead to beta cell toxicity.  This toxicity 
is named “glucolipotoxicity” because it is induced by the synergistic effect of fatty acids and 
glucose, leading to impairment of insulin secretion and expression as well as beta cell apoptosis 
(1, 2). The decline in beta cell function plays a central role in the development of type-2 
diabetes.  To understand and find a treatment for type-2 diabetes, the mechanism of the 
glucolipotoxicity needs to be well understood.  Several intermediates have been suggested to 
play a role in the glucolipotoxicity process. Lipids in the glycerolipids pathway, ceramides and 
cholesterol intermediates have been suggested to be candidates’ signals for inducing cell 
toxicity (2-4). Free radical generation was also suggested as a part of the glucolipotoxicity effect 
on beta cells (3). 
  Recently a glucolipotoxicity study using INS-1 cells showed changes in the expression of 
many genes, increase in lipid synthesis as well as changes in TCA cycle intermediates (5). This 
research interestingly showed that glucose induced increase in TCA cycle intermediates is 
attenuated in the lipotoxic model (5). These results were similar to the results obtained in our 
lab, were a lipotoxic model of INS-1 cells showed lower glucose flux in TCA cycle (unpublished 
data). Our lab data showed several metabolomics changes induced by glucolipotoxicity, among 




in malate induced by aspartate through the asp-mal shuttle was significantly attenuated, 
suggesting a defect in this shuttle.   
  Aspartate plays an important role in insulin secretion (6) since it acts as an anaplerotic 
substrate for TCA cycle and provides enough malate for TCA cycle through the asp-mal shuttle.  
The defect in asp-mal shuttle in lipotoxic models could be due to the interaction of fatty acid 
with proteins in this shuttle. An interesting hypothesis is that fatty acids modify proteins 
involved in GSIS thus affecting their function. Fatty acids like palmitic acid can covalently attach 
to proteins through a thio-ester bond in a process called palmitoylation. It was recently shown 
that many proteins including those involved in the asp-mal shuttle are palmitoylated (7, 8) and 
this palmitoylation can be inhibited by 2-bromopalmitate (9). Dynamic palmitoylation is 
reversed by enzymes named lysophospholipase 1 and 2 (LYPLA1 and LYPLA2), which can 
depamitoylate proteins (10, 11)  . The extensive palmitoylation of proteins suggested its 
important role in obesity related diseases (8) and it was recently shown that inhibition of 
palmitoylation using bromopalmitate reduced palmitate induced toxicity in beta cells (12). 
  LYPLA inhibitors were recently developed to treat some forms of cancers (11) and at the 
same time prevent the depalmitoylation step. As a preliminary data, we tested on some of 
these LYPLA inhibitors on INS-1 cells and interestingly the changes detected were mainly in the 
malate and aspartate levels (figure 1). Therefore a future work would suggest testing the 
hypothesis that palmitoylation of asp-malate shuttle is involved in the defect of GSIS in 
lipotoxicity model. Future work should also involve the inhibition of palmitoylation by 




   
 
Figure ‎6-1: showing the effect of palmitoylation inhibitors on metabolites levels in INS-1 cells (left) and a proposed 
hypothesis for the effect of fatty acid on aspartate malate shuttle (right). 
  We have shown in chapter 4, that fatty acid increase the TCA cycle activity and glucose 
oxidation. Thus, the decrease in asp-shuttle activity could also arise from the depletion of 
aspartate, which is being consumed to feed the “very active” TCA cycle. Thus a supply of 
aspartate could restore the beta cell secretory function and its response to glucose. 
Interestingly, increasing glutamate conversion into α-Ketoglutarate by BCH decreased cell death 
in glucolipotoxic cell model (13). This would confirm our suggestion for the importance of TCA 
cycle in mediating the effect of glucolipotoxity. 
Other secretagogues 
  As described in chapter 1, different secretagogues like leucine, α-ketoisocaproate (KIC) 
and monomethyl succinate (MMS) can stimulate insulin secretion. Addition of KIC alone will not 
stimulate insulin secretion but the addition of KIC with MMS will stimulate insulin secretion in 
INS-1 cells. Some metabolic couplers are being generated from these secretagogues that 
stimulate insulin secretion. Although the mechanisms for different secretagogues were 
described   in chapter 1, there are still many unanswered question. Among these questions are: 
What are the metabolic couplers or pathways that are activated by MMS addition to KIC and 
leads to insulin secretion? Why is leucine less effective than glucose in stimulating insulin 




Preliminary data were obtained comparing U-13C glucose vs U-13C KIC or U-13C KIC+ 
MMS. U-13C glucose increased the unlabeled malate (coming from aspartate) (figure 2) as we 
have shown before in chapter 3. KIC did not induce this increase; however the addition of MMS 
increased the unlabeled Malate. The increase in unlabeled Malate could be coming from the 
MMS itself, by supplying succinate to the TCA cycle, since aspartate levels did not change 
(figure 3).  
 
 
Figure ‎6-2: Isotope distribution of aspartate and malate after stimulation with U
13
C-labeled glucose or KIC.  
This would suggest that although KIC could not stimulate the asp-mal shuttle, addition 
of MMS acted as anaplerotic substrate rather than aspartate. However KIC+MMS were not as 
efficient as glucose in increasing malate or reducing aspartate.  
Away from the asp-mal shuttle, glucose was also able to increase flux in the mevalonate 
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pathway was suggested to play a role in insulin secretion (14). Interestingly KIC alone did not increase 
the flux in this pathway, while the addition of MMS increased the flux (figure 3), suggesting a novel role 
for these combination of nutrients.  
 
Figure ‎6-3: HMG-CoA isotope distribution after INS-1 stimulation with different nutrients. 
Finally, these preliminary data would provide a novel insight on the mechanism of these 
secretagogues. Further follow up experiments are required to investigate the importance of the 
mevalonic pathway in mediating the insulin secretion response for these secretagogues 
combination.  
Human beta cell lines 
     Human beta cell lines were successfully generated in different labs (15, 16). This 
development will open the doors towards the treatment of insulin dependent diabetic patients.  
The novel human beta cell lines were shown to be responsive to glucose and other 
secretagogues (16). Glucotoxicity (17) and lipotoxicity (18) were studied on this novel cell line 
and cells showed impairment of GSIS similar to what was shown before in rodent cell lines and 
islets. Changes in gene expression and increase in cell apoptosis was shown in those cells when 
exposed to high glucose or fatty acid (17, 18).  
  So far, there is no metabolomics study that has studied these cell lines. It is important to 
compare metabolites changes between human and rodents’ cell lines during insulin secretion, 





























This comparison is also important during glucolipotoxicity stages to discover new therapies that 
can restore human beta cell function.  
Islets from human and rodents 
   Islets from human or from rodents represent a more physiological model for studying 
metabolic signaling during insulin secretion. Drawbacks of using islets are mentioned in chapter 
1. A recent published metabolomics study performed on rat islets (19) using 240 islets for each 
time points. They were able to identify 31 metabolites changing with glucose stimulation, while 
in INS-1 cells we have monitored changes in ~70 metabolites during GSIS, without including 
glycerolipids species. The low number of identified islets metabolites in the previous study can 
be attributed to sample preparation and analysis. For sample preparation, extraction solvent 
for islets can be optimized to avoid sample dilution and increase the metabolites signal to noise 
ratio. For analysis, LC-MS can be used rather than the GC-MS used in this published study since 
the latter suffer from several drawbacks described in chapter 1. LC-MS can be further improved 
by using UPLC and nano ESI for the small and precious islets sample as described in the next 
section and in chapter 1.  
UPLC and nano electrospray  
    As described in chapter 1, electrospray ionization is the most widely used ionization 
technique using in mass spectrometer.  ESI provides the widest coverage of metabolome 
compared to other ionization techniques. However, one of the major drawbacks of ESI that low 
abundant metabolites are prone to ionization suppression from more abundant metabolites. 
The ideal scenario to avoid the ionization suppression is to have 1 ion per droplet sprayed into 
the mass spec. Nano flow LC coupled to nano spray ESI try to achieve flow rates of ~ 200 
nl/minute to gain this improvement in sensitivity.  UPLC provide a complementary increase in 
sensitivity by achieving better separation and narrower peaks. As described in chapter 1, 
narrower peaks will increase signal to noise ratio and allow the detection of many hidden 
metabolites. It is worth mentioning that the NH2 column is ideal for polar metabolites analysis 
as well as some lipid classes, but it suffers from column bleeding in high pH and hence very 
short column life compared to a reverse phase column. Hence improvement of the stationary 
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Appendix -Flux in metabolic pathways using labeled nutrients. 
Metabolic tracers: 
 
a) U-13C Glucose: 
Glucose can be used to monitor several pathways, including glycolysis, TCA cycle, pentose phosphate 
pathway, purine and pyrimidine pathways as well as glycerolipids synthesis pathway. Using 13C glucose is 
very useful in beta cell studies, since glucose is the most powerful stimulant for insulin secretion and it 
allows the monitoring of different pathways involved in insulin secretion. 
 
Figure A-1: Some of the metabolic pathways that can be probed using U-13C glucose. 
Experimental conditions 
- INS-1 cells were incubated at low glucose for several hours (~ 6 hours) before 
completely depriving them of glucose for 30 minutes. This treatment ensures the best 
uptake of the U-13C glucose, without being diluted by any other unlabeled glucose. 
- To avoid the utilization of nutrients other than glucose, experiments were performed in 






Glucose can probe several pathways as described in the previous section; however some nutrients, such 
as amino acids can be used to probe specific pathways. One of the widely used amino acids is glutamine 
which acts as an anaplerotic substrate and is widely used to probe flux in the TCA cycle (1) (figure 2). 
 
Figure A-2: metabolic pathways that can be probed using U-13C glutamic acid 
Experimental conditions: 
- INS-1 cells were starved from glutamine for 6 hours (at 3 mM  glucose), before the addition of 2 
mM labeled glutamine for 30 minutes in KRHB and no glucose. This treatment resulted in ~ 50% 
labeled glutamate, aspartate and malate.  Addition of unlabeled glucose increased the uptake of 
labeled glutamic acid into the TCA cycle (figure 3). 
       






















































Ethanolamine can be used to monitor flux in the Kennedy pathway of 
phosphatidylethanolamine synthesis (figure 4).  Phosphoethanolamine and CDP-ethanolamine 
are polar  metabolites that can be monitored using the HILIC method, while 
phosphatidylethanolamine can be monitored using a lipid separation method. 
                 
Figure A-4: metabolic pathways that can be probed using labeled ethanolamine. Left: Kennedy pathways 
for PE synthesis. Middle: chromatogram showing the intensity of labeled and unlabeled CDP-
ethanolamine. Right: The ratio of labeled PE to unlabeled PE after 1 hour incubation with labeled 
ethanolamine. 
Experimental conditions: 
- The concentration of ethanolamine used in the experiment was 160 µM which is ~ 8 times the 
concentration originally used in advanced RPMI media (~ 20 µM). INS-1 cells could be incubated 
in RPMI or in KRHB during the experiment; however, glucose presence is crucial to allow for 
lipogenesis. 
- One hour incubation with 160 µM ethanolamine achieved  50% labeling in CDP-Et (figure 4 ) and 
achieved  14 % labeling in PE (34:1) (figure 4)  
Note: ethanolamine is an ion pairing agent that can change RPC column binding affinity; however the most 
dramatic effect will be seen in the mass spec in the positive mode, where a large peak of the ethanolamine will be 
seen in the background of subsequent runs. Washing the LC-MS system with IPA and acetonitrile is recommended 

















Choline can be used to monitor flux in the Kennedy pathway of PC synthesis (figure 5). 
Phosphocholine and CDP-choline are polar metabolites that can be monitored using the HILIC 
method, while PC should be monitored using a lipid separation method. Phosphocholine and 
CDP-choline can be ionized in the negative mode by monitoring the M-H ion, but also by 
observing the acetate adduct formed due to the presence of the choline group. 
      
Figure A-5: metabolic pathways that can be probed using labeled choline. Left: Kennedy pathway for PC 
synthesis. Middle: the percentage labeling in polar fraction after 1 hour incubation with labeled choline. 
Right: labeling ratio of PC and LPC after 24 hour incubation in labeled choline in RPMI. 
Experimental conditions: 
- D9-choline chloride was used in the range of 200 µM - 1000 µM which is approximately 10- 50 
times the concentration used in normal RPMI media (20 µM). INS-1 cells could be incubated in 
RPMI or in KRHB during the experiment; however, glucose presence is crucial to allow for 
lipogenesis. 
- One hour of incubation with 200 µM choline chloride resulted in approximately 12 and 15 % of 
labeling in phosphocholine and CDP-choline. This low percentage is because of the endogenous 
large pool of those metabolites. Incubation of cells in RPMI supplied with 1000 µM D9-choline 
for 24 hours achieved approximately 50 % labeling in major PC forms like PC (34:1) and 20% in 
LPC (16:0). 
Note: Deuterated compounds are unstable compared to 
13
-C carbon labeled compounds, they can exchange with 

















































Serine can be used to monitor flux into phosphatidyl serine. There are no polar intermediates 
except serine in this pathway. PS can only be generated indirectly in mammalian cells from PC 
or PE by PS synthase 1 or 2 (PSS-1 and PSS-2) respectively. Owing to the large pool of PC and PE, 
it is hard to anticipate which form of PS will be formed. This makes HILIC, which separates lipids 
based on their head group, an ideal option for PS measurements.  
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Figure A-6: metabolic pathways that can be monitored using serine. Upper: PS synthesis pathway from 
PE and PC. Lower left: mass spectrum showing the labeling in PS (34:1) and PS (36:1). Lower right: ratio 
of labeled to unlabeled PS after 1 hour incubation with labeled serine. 
Experimental conditions  
- The concentration of +7 serine (C3, D3, 
15N) serine used in the experiment was 1 mM which is 5 
times the concentration originally used in RPMI (~ 200 µM).  INS-1 Cells could be incubated in 
RPMI or KRHB during the experiment, however, KRHB was be preferred to avoid any dilution 
from unlabeled serine in the RPMI media. 
- INS-1 cells were incubated in KRHB with the +7 serine and low glucose (2 mM) for 1 hour before 
stimulation with 10 mM glucose for 30 minutes. This treatment resulted in ~ 10 % labeling in PS 







Labeled fatty acids can be used to monitor flux into all phospholipid classes at short time points, except 
for PS, which needs extensive labeling in PE and PC first before it can be detected in PS. Lipid species 
formed are dependent on the fatty acid precursor added, for example, the addition of palmitic acid 
(16:0) will form the palmitoyl species of carnitine and LPA, while forming the dipalmitoyl species of PA, 
PE,PI,DAG,PC,PE. These forms will be in addition to the formation of oleic and palmitoyl combinations 
(18:1, 16:0) or (34:1). 
      
Figure A-7: Metabolic pathways of fatty acid. Left:  diagram showing the pathway of fatty acid. Right: the 
levels of DAG (34:1) or DAG (32:0) after incubation with 100 µM +16 fatty acid with 10 mM glucose for 
30 minutes. 
Experimental conditions: 
- The concentration of labeled fatty acid used ranged from 10 µM to 500 µM. The usage of U-13C 
palmitate or U-13C Oleate results in +16 or +18 mass shift for each fatty acid added in the lipid 
respectively. Glucose presence depends on the goal of experiment. Glucose will provide the 
glycerol back bone needed to synthesize glycerolipids; however this will consume long chain 
CoAs and reduces their intracellular levels. Fatty acid oxidation will be reduced in the presence 
of glucose, thus reducing the level of acyl-carnitines.  
- Incubation of INS-1 cells with 100 µM of U-13C palmitic acid with 10 mM glucose for 30 minutes 
resulted in 40% labeling in the abundant DAG (34:1) and 95 % labeling in the less abundant DAG 


























Summary and conclusion   
We have described the application of different metabolic tracers to probe different metabolic 
pathways. Metabolic tracers described here include glucose, glutamine, choline, ethanolamine, 
serine and fatty acids. The culture conditions and concentration used for those metabolic 
tracers were described, together with the expected results within a specific time frame. 
Depending on the goal of the experiment, these metabolic tracers can be used in the absence 
or presence of glucose.  The applications of the previously mentioned metabolic tracers are 
summarized in figure 8. 
 
 Figure A-8: General metabolic pathways and possible metabolic tracers. 
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